Jeffrey Bluestone, PhD
Professor Emeritus
Diabetes Center
School of Medicine

He and members of his lab have developed soluble receptor antagonists; monoclonal antibodies and animals deficient in individual members of TCR and co-stimulatory pathways to define their individual roles in transplant rejection and autoimmunity including a special emphasis on a specialized subset of T cells termed “regulatory T cells” (Treg). Tregs control fundamental aspect of immune homeostasis. During the last several years, his research has adapted the animal studies using biologics and cell based therapies to develop therapeutics that can be used in humans with autoimmunity and under conditions of allotransplant rejection. Moreover, a strong role for antigen-specific Tregs have been found in these model systems and further evidence in humanized mice and transplant patients that alloantigen-specific Tregs are more effective. Thus, the major goal of this work is to identify the antigen-specificity of thymic- and peripherally-derived Tregs with the expectation that these TCRs can be adapted for immunotherapy. Finally, his lab initiated several projects to determine mechanisms that control Treg stability. The goal is to develop approaches using pharmacogenomics to either stabilize or destabilize Tregs in autoimmunity and cancer.

In March 2010 Dr. Bluestone was appointed executive vice chancellor and provost at the University of California San Francisco (UCSF) serving as chief academic officer guiding the research and academic enterprise advancing the campus priorities in close collaboration with the chancellor and the campus leadership teams, and to oversee the campus ethics and compliance enterprise. Previously he served in a number of posts including Director of theUCSF Diabetes Center, as Director of the Immune Tolerance Network.

In June 2008 Dr. Bluestone served as interim vice chancellor of research; directing the advancement of cross-campus research initiatives, such as enhancing core research facilities. In this capacity, he played a leading role in coordinating and integrating current research cores. He worked also to strengthen external research partnerships, particularly with industry, and focused on facilitating the translation of UCSF discoveries into public benefit.

In 2009, Dr. Bluestone led the UCSF committee to strategize and secure funds available through the American Recovery and Reinvestment Act, making the campus one of the top institutional recipients in the nation of science-based stimulus funds.

Dr. Bluestone joined the UCSF faculty in 2000. He is an international leader in the field of immunotherapy, with a stellar record of scholarly achievement and a decade of significant contributions to the research enterprise at UCSF, including the creation and directorship of an integrated UCSF Diabetes Center to focus on translating basic research in both type 1 and type 2 diabetes into improved therapies for patients. He also founded and directed the Immune Tolerance Network, a consortium of more than 1,000 of the world’s leading scientific researchers and clinical specialists from nearly 50 institutions, with the mission of testing new therapies to promote immune tolerance in transplantation, autoimmune diseases, asthma and allergic diseases.

As a research scientist, Dr. Bluestone has helped clarify the body’s immune response on a molecular level. His systematic investigation has catalyzed recent progress in stem cell research, islet cell transplantation and immune tolerance therapies – experimentation that has formidably translated into drugs to treat human disease.

Through his 30-year scientific career, he has authored more than 300 peer-reviewed publications that include prominent papers in Nature, Nature Immunology, and the Journal of Immunology and Diabetes. He has received numerous accolades for his work, including his 2006 election to the American Academy of Arts and Sciences, the Mary Tyler Moore & Robert Levine Excellence in Clinical Research Award from the Juvenile Diabetes Research Foundation, and the distinguished alumni award from the Cornell Graduate School of Medical Science.

Prior to joining UCSF, Bluestone was at the University of Chicago, where he was a member of the Ben May Institute for Cancer Research, rising over 13 years from an associate professor to the director of the institute. He had previously worked for seven years in various roles at the National Cancer Institute of the National Institutes of Health, ultimately becoming a senior investigator in the Immunology Branch of the National Cancer Institute.

Dr. Bluestone earned both his BS in biology and his MS in microbiology from Rutgers State University, and his PhD in immunology from the Cornell Graduate School of Medical Science (Sloan-Kettering Division).

• Opportunities for Treg cell therapy for the treatment of human disease.
  Frontiers in immunology 2023 Bluestone JA, McKenzie BS, Beilke J, Ramsdell F
• Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor-Induced Hypophysitis.
  Journal of the Endocrine Society 2023 Quandt Z, Kim S, Villanueva-Meyer J, Coupe C, Young A, Kang JH, Yazdany J, Schmajuk G, Rush S, Ziv E, Perdigoto AL, Herold K, Lechner MG, Su MA, Tyrrell JB, Bluestone J, Anderson M, Masharani U
• Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies.
  Science translational medicine 2022 Goodman DB, Azimi CS, Kearns K, Talbot A, Garakani K, Garcia J, Patel N, Hwang B, Lee D, Park E, Vykunta VS, Shy BR, Ye CJ, Eyquem J, Marson A, Bluestone JA, Roybal KT
• Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection.
  Cell reports 2022 VanDyke D, Iglesias M, Tomala J, Young A, Smith J, Perry JA, Gebara E, Cross AR, Cheung LS, Dykema AG, Orcutt-Jahns BT, Henclová T, Golias J, Balolong J, Tomasovic LM, Funda D, Meyer AS, Pardoll DM, …
• BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes.
  Blood 2022 Zaiken MC, Flynn R, Paz KG, Rhee SY, Jin S, Mohamed FA, Saha A, Thangavelu G, Park PMC, Hemming ML, Sage PT, Sharpe AH, DuPage M, Bluestone JA, Panoskaltsis-Mortari A, Cutler CS, Koreth J, Antin JH, …
• Multiple early factors anticipate post-acute COVID-19 sequelae.
  Cell 2022 Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, Li S, Hong S, Zhang R, Xie J, Kornilov SA, Scherler K, Pavlovitch-Bedzyk AJ, Dong S, Lausted C, Lee I, Fallen S, Dai CL, Baloni P, Smith B, Duvvuri VR, …
• Polyclonal Regulatory T Cell Manufacturing Under cGMP: A Decade of Experience.
  Frontiers in immunology 2021 Balcerek J, Shy BR, Putnam AL, Masiello LM, Lares A, Dekovic F, Acevedo L, Lee MR, Nguyen V, Liu W, Paruthiyil S, Xu J, Leinbach AS, Bluestone JA, Tang Q, Esensten JH
• The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes.
  JCI insight 2021 Dong S, Hiam-Galvez KJ, Mowery CT, Herold KC, Gitelman SE, Esensten JH, Liu W, Lares AP, Leinbach AS, Lee M, Nguyen V, Tamaki SJ, Tamaki W, Tamaki CM, Mehdizadeh M, Putnam AL, Spitzer MH, Ye CJ, Tang …
• Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.
  Frontiers in immunology 2021 Muller YD, Ferreira LMR, Ronin E, Ho P, Nguyen V, Faleo G, Zhou Y, Lee K, Leung KK, Skartsis N, Kaul AM, Mulder A, Claas FHJ, Wells JA, Bluestone JA, Tang Q
• Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR.
  Journal for immunotherapy of cancer 2021 Bayless NL, Bluestone JA, Bucktrout S, Butterfield LH, Jaffee EM, Koch CA, Roep BO, Sharpe AH, Murphy WJ, Villani AC, Walunas TL
• Immunotherapy: Building a bridge to a cure for type 1 diabetes.
  Science (New York, N.Y.) 2021 Bluestone JA, Buckner JH, Herold KC
• Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
  The lancet. Diabetes & endocrinology 2021 Gitelman SE, Bundy BN, Ferrannini E, Lim N, Blanchfield JL, DiMeglio LA, Felner EI, Gaglia JL, Gottlieb PA, Long SA, Mari A, Mirmira RG, Raskin P, Sanda S, Tsalikian E, Wentworth JM, Willi SM, …
• The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28.
  Frontiers in immunology 2021 Muller YD, Nguyen DP, Ferreira LMR, Ho P, Raffin C, Valencia RVB, Congrave-Wilson Z, Roth TL, Eyquem J, Van Gool F, Marson A, Perez L, Wells JA, Bluestone JA, Tang Q
• Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines.
  Trends in immunology 2021 Kang JH, Bluestone JA, Young A
• At the Heart of Immune Checkpoint Inhibitor-Induced Immune Toxicity.
  Cancer discovery 2021 Young A, Bluestone JA
• Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19.
  Cell 2020 Su Y, Chen D, Yuan D, Lausted C, Choi J, Dai CL, Voillet V, Duvvuri VR, Scherler K, Troisch P, Baloni P, Qin G, Smith B, Kornilov SA, Rostomily C, Xu A, Li J, Dong S, Rothchild A, Zhou J, Murray K, …
• Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis.
  Science immunology 2020 Lee JC, Mehdizadeh S, Smith J, Young A, Mufazalov IA, Mowery CT, Daud A, Bluestone JA
• Solving the Puzzle of Immune Tolerance for β-Cell Replacement Therapy for Type 1 Diabetes.
  Cell stem cell 2020 Bluestone JA, Tang Q
• Functional CRISPR dissection of gene networks controlling human regulatory T cell identity.
  Nature immunology 2020 Schumann K, Raju SS, Lauber M, Kolb S, Shifrut E, Cortez JT, Skartsis N, Nguyen VQ, Woo JM, Roth TL, Yu R, Nguyen MLT, Simeonov DR, Nguyen DN, Targ S, Gate RE, Tang Q, Bluestone JA, Spitzer MH, Ye CJ,…
• Tolerance in the Age of Immunotherapy.
  The New England journal of medicine 2020 Bluestone JA, Anderson M
• Multiomic Immunophenotyping of COVID-19 Patients Reveals Early Infection Trajectories.
  bioRxiv : the preprint server for biology 2020 Su Y, Chen D, Lausted C, Yuan D, Choi J, Dai C, Voillet V, Scherler K, Troisch P, Duvvuri VR, Baloni P, Qin G, Smith B, Kornilov S, Rostomily C, Xu A, Li J, Dong S, Rothchild A, Zhou J, Murray K, …
• Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials.
  Lancet (London, England) 2020 Sawitzki B, Harden PN, Reinke P, Moreau A, Hutchinson JA, Game DS, Tang Q, Guinan EC, Battaglia M, Burlingham WJ, Roberts ISD, Streitz M, Josien R, Böger CA, Scottà C, Markmann JF, Hester JL, …
• CRISPR screen in regulatory T cells reveals modulators of Foxp3.
  Nature 2020 Cortez JT, Montauti E, Shifrut E, Gatchalian J, Zhang Y, Shaked O, Xu Y, Roth TL, Simeonov DR, Zhang Y, Chen S, Li Z, Woo JM, Ho J, Vogel IA, Prator GY, Zhang B, Lee Y, Sun Z, Ifergan I, Van Gool F, …
• Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies.
  Cell 2020 Roth TL, Li PJ, Blaeschke F, Nies JF, Apathy R, Mowery C, Yu R, Nguyen MLT, Lee Y, Truong A, Hiatt J, Wu D, Nguyen DN, Goodman D, Bluestone JA, Ye CJ, Roybal K, Shifrut E, Marson A
• Accelerating the development of innovative cellular therapy products for the treatment of cancer.
  Cytotherapy 2020 Stewart MD, Keane A, Butterfield LH, Levine BL, Thompson B, Xu Y, Ramsborg C, Lee A, Kalos M, Koerner C, Moore T, Markovic I, Lasiter L, Ibrahim R, Bluestone J, Sigal E, Allen J
• Cutting Edge: IL-6-Driven Immune Dysregulation Is Strictly Dependent on IL-6R α-Chain Expression.
  Journal of immunology (Baltimore, Md. : 1950) 2020 Mufazalov IA, Andruszewski D, Schelmbauer C, Heink S, Blanfeld M, Masri J, Tang Y, Schüler R, Eich C, Wunderlich FT, Karbach SH, Bluestone JA, Korn T, Waisman A
• New Frontiers in the Treatment of Type 1 Diabetes.
  Cell metabolism 2019 Warshauer JT, Bluestone JA, Anderson MS
• Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency.
  Nature biotechnology 2019 Nguyen DN, Roth TL, Li PJ, Chen PA, Apathy R, Mamedov MR, Vo LT, Tobin VR, Goodman D, Shifrut E, Bluestone JA, Puck JM, Szoka FC, Marson A
• Treg cell-based therapies: challenges and perspectives.
  Nature reviews. Immunology 2019 Raffin C, Vo LT, Bluestone JA
• Thymically-derived Foxp3+ regulatory T cells are the primary regulators of type 1 diabetes in the non-obese diabetic mouse model.
  PloS one 2019 Holohan DR, Van Gool F, Bluestone JA
• Next-generation regulatory T cell therapy.
  Nature reviews. Drug discovery 2019 Ferreira LMR, Muller YD, Bluestone JA, Tang Q
• An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
  The New England journal of medicine 2019 Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, …
• NextGen cell-based immunotherapies in cancer and other immune disorders.
  Current opinion in immunology 2019 Azimi CS, Tang Q, Roybal KT, Bluestone JA
• A Mutation in the Transcription Factor Foxp3 Drives T Helper 2 Effector Function in Regulatory T Cells.
  Immunity 2019 Van Gool F, Nguyen MLT, Mumbach MR, Satpathy AT, Rosenthal WL, Giacometti S, Le DT, Liu W, Brusko TM, Anderson MS, Rudensky AY, Marson A, Chang HY, Bluestone JA
• Adoptive Treg Cell Therapy in a Patient With Systemic Lupus Erythematosus.
  Arthritis & rheumatology (Hoboken, N.J.) 2019 Dall'Era M, Pauli ML, Remedios K, Taravati K, Sandova PM, Putnam AL, Lares A, Haemel A, Tang Q, Hellerstein M, Fitch M, McNamara J, Welch B, Bluestone JA, Wofsy D, Rosenblum MD, Autoimmunity Centers …
• Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer.
  Frontiers in medicine 2018 Bridge JA, Lee JC, Daud A, Wells JW, Bluestone JA
• The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy.
  Cancer immunology research 2018 Young A, Quandt Z, Bluestone JA
• Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again.
  Genome medicine 2018 Bucktrout SL, Bluestone JA, Ramsdell F
• Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier.
  The Journal of allergy and clinical immunology 2018 Esensten JH, Muller YD, Bluestone JA, Tang Q
• Treg cells-the next frontier of cell therapy.
  Science (New York, N.Y.) 2018 Bluestone JA, Tang Q
• Chance favours the prepared mind.
  Nature reviews. Immunology 2018 Bluestone JA
• Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy.
  Journal of immunology (Baltimore, Md. : 1950) 2018 Spangler JB, Trotta E, Tomala J, Peck A, Young TA, Savvides CS, Silveria S, Votavova P, Salafsky J, Pande VS, Kovar M, Bluestone JA, Garcia KC
• Revisiting IL-2: Biology and therapeutic prospects.
  Science immunology 2018 Abbas AK, Trotta E, R Simeonov D, Marson A, Bluestone JA
• Author Correction: Discovery of stimulation-responsive immune enhancers with CRISPR activation.
  Nature 2018 Simeonov DR, Gowen BG, Boontanrart M, Roth TL, Gagnon JD, Mumbach MR, Satpathy AT, Lee Y, Bray NL, Chan AY, Lituiev DS, Nguyen ML, Gate RE, Subramaniam M, Li Z, Woo JM, Mitros T, Ray GJ, Curie GL, …
• A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism.
  Nature medicine 2018 Trotta E, Bessette PH, Silveria SL, Ely LK, Jude KM, Le DT, Holst CR, Coyle A, Potempa M, Lanier LL, Garcia KC, Crellin NK, Rondon IJ, Bluestone JA
• Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.
  Diabetes 2018 Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC
• Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity.
  Cell reports 2018 Wang D, Quiros J, Mahuron K, Pai CC, Ranzani V, Young A, Silveria S, Harwin T, Abnousian A, Pagani M, Rosenblum MD, Van Gool F, Fong L, Bluestone JA, DuPage M
• Stem Cell Therapies for Treating Diabetes: Progress and Remaining Challenges.
  Cell stem cell 2018 Sneddon JB, Tang Q, Stock P, Bluestone JA, Roy S, Desai T, Hebrok M
• Pathological conversion of regulatory T cells is associated with loss of allotolerance.
  Scientific reports 2018 Hua J, Inomata T, Chen Y, Foulsham W, Stevenson W, Shiang T, Bluestone JA, Dana R
• Revealing the specificity of regulatory T cells in murine autoimmune diabetes.
  Proceedings of the National Academy of Sciences of the United States of America 2018 Spence A, Purtha W, Tam J, Dong S, Kim Y, Ju CH, Sterling T, Nakayama M, Robinson WH, Bluestone JA, Anderson MS, Tang Q
• Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes.
  Science (New York, N.Y.) 2018 Sockolosky JT, Trotta E, Parisi G, Picton L, Su LL, Le AC, Chhabra A, Silveria SL, George BM, King IC, Tiffany MR, Jude K, Sibener LV, Baker D, Shizuru JA, Ribas A, Bluestone JA, Garcia KC
• Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization.
  Frontiers in immunology 2018 Fuchs A, Gliwinski M, Grageda N, Spiering R, Abbas AK, Appel S, Bacchetta R, Battaglia M, Berglund D, Blazar B, Bluestone JA, Bornhäuser M, Ten Brinke A, Brusko TM, Cools N, Cuturi MC, Geissler E, …
• Future cancer research priorities in the USA: a Lancet Oncology Commission.
  The Lancet. Oncology 2017 Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, …
• Avidity and Bystander Suppressive Capacity of Human Regulatory T Cells Expressing De Novo Autoreactive T-Cell Receptors in Type 1 Diabetes.
  Frontiers in immunology 2017 Yeh WI, Seay HR, Newby B, Posgai AL, Moniz FB, Michels A, Mathews CE, Bluestone JA, Brusko TM
• Discovery of stimulation-responsive immune enhancers with CRISPR activation.
  Nature 2017 Simeonov DR, Gowen BG, Boontanrart M, Roth TL, Gagnon JD, Mumbach MR, Satpathy AT, Lee Y, Bray NL, Chan AY, Lituiev DS, Nguyen ML, Gate RE, Subramaniam M, Li Z, Woo JM, Mitros T, Ray GJ, Curie GL, …
• Polyclonal Regulatory T Cell Therapy for Control of Inflammation in Kidney Transplants.
  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2017 Chandran S, Tang Q, Sarwal M, Laszik ZG, Putnam AL, Lee K, Leung J, Nguyen V, Sigdel T, Tavares EC, Yang JYC, Hellerstein M, Fitch M, Bluestone JA, Vincenti F
• Corrigendum: Is autoimmunity the Achilles' heel of cancer immunotherapy?
  Nature medicine 2017 June CH, Warshauer JT, Bluestone JA
• Is autoimmunity the Achilles' heel of cancer immunotherapy?
  Nature medicine 2017 June CH, Warshauer JT, Bluestone JA
• Targeting ABL-IRE1α Signaling Spares ER-Stressed Pancreatic β Cells to Reverse Autoimmune Diabetes.
  Cell metabolism 2017 Morita S, Villalta SA, Feldman HC, Register AC, Rosenthal W, Hoffmann-Petersen IT, Mehdizadeh M, Ghosh R, Wang L, Colon-Negron K, Meza-Acevedo R, Backes BJ, Maly DJ, Bluestone JA, Papa FR
• Targeting ABL-IRE1α Signaling Spares ER-Stressed Pancreatic β Cells to Reverse Autoimmune Diabetes.
  Cell metabolism 2017 Morita S, Villalta SA, Feldman HC, Register AC, Rosenthal W, Hoffmann-Petersen IT, Mehdizadeh M, Ghosh R, Wang L, Colon-Negron K, Meza-Acevedo R, Backes BJ, Maly DJ, Bluestone JA, Papa FR
• FOXP3, the Transcription Factor at the Heart of the Rebirth of Immune Tolerance.
  Journal of immunology (Baltimore, Md. : 1950) 2017 Bluestone JA
• Expansion of Human Tregs from Cryopreserved Umbilical Cord Blood for GMP-Compliant Autologous Adoptive Cell Transfer Therapy.
  Molecular therapy. Methods & clinical development 2016 Seay HR, Putnam AL, Cserny J, Posgai AL, Rosenau EH, Wingard JR, Girard KF, Kraus M, Lares AP, Brown HL, Brown KS, Balavage KT, Peters LD, Bushdorf AN, Atkinson MA, Bluestone JA, Haller MJ, Brusko TM
• Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials.
  Annual review of pathology 2016 Esensten JH, Bluestone JA, Lim WA
• CD28 Costimulation: From Mechanism to Therapy.
  Immunity 2016 Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA
• Correction: CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis.
  Journal of immunology (Baltimore, Md. : 1950) 2016 Roan F, Stoklasek TA, Whalen E, Molitor JA, Bluestone JA, Buckner JH, Ziegler SF
• Regulatory T cell therapy for type 1 diabetes: May the force be with you.
  Journal of autoimmunity 2016 Gitelman SE, Bluestone JA
• Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial.
  Diabetologia 2016 Gitelman SE, Gottlieb PA, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Harris KM, Kanaparthi S, Phippard D, Ding L, Bluestone JA, Ehlers MR, ITN START …
• Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease.
  Nature reviews. Immunology 2016 DuPage M, Bluestone JA
• CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis.
  Journal of immunology (Baltimore, Md. : 1950) 2016 Roan F, Stoklasek TA, Whalen E, Molitor JA, Bluestone JA, Buckner JH, Ziegler SF
• Inducing and Administering Tregs to Treat Human Disease.
  Frontiers in immunology 2016 Perdigoto AL, Chatenoud L, Bluestone JA, Herold KC
• Type 1 diabetes immunotherapy using polyclonal regulatory T cells.
  Science translational medicine 2015 Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q
• Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction.
  Molecular genetics and metabolism 2015 Kishnani PS, Dickson PI, Muldowney L, Lee JJ, Rosenberg A, Abichandani R, Bluestone JA, Burton BK, Dewey M, Freitas A, Gavin D, Griebel D, Hogan M, Holland S, Tanpaiboon P, Turka LA, Utz JJ, Wang YM, …
• Shifting the Evolving CAR T Cell Platform into Higher Gear.
  Cancer cell 2015 Holohan DR, Lee JC, Bluestone JA
• Targeting Treg signaling for the treatment of autoimmune diseases.
  Current opinion in immunology 2015 Spence A, Klementowicz JE, Bluestone JA, Tang Q
• Generation of knock-in primary human T cells using Cas9 ribonucleoproteins.
  Proceedings of the National Academy of Sciences of the United States of America 2015 Schumann K, Lin S, Boyer E, Simeonov DR, Subramaniam M, Gate RE, Haliburton GE, Ye CJ, Bluestone JA, Doudna JA, Marson A
• Interleukin-33 and Interferon-γ Counter-Regulate Group 2 Innate Lymphoid Cell Activation during Immune Perturbation.
  Immunity 2015 Molofsky AB, Van Gool F, Liang HE, Van Dyken SJ, Nussbaum JC, Lee J, Bluestone JA, Locksley RM
• Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226.
  Journal of immunology (Baltimore, Md. : 1950) 2015 Fuhrman CA, Yeh WI, Seay HR, Saikumar Lakshmi P, Chopra G, Zhang L, Perry DJ, McClymont SA, Yadav M, Lopez MC, Baker HV, Zhang Y, Li Y, Whitley M, von Schack D, Atkinson MA, Bluestone JA, Brusko TM
• IL-2: Change Structure … Change Function.
  Immunity 2015 Bluestone JA, Crellin N, Trotta E
• T cells in the control of organ-specific autoimmunity.
  The Journal of clinical investigation 2015 Bluestone JA, Bour-Jordan H, Cheng M, Anderson M
• The therapeutic potential of regulatory T cells for the treatment of autoimmune disease.
  Expert opinion on therapeutic targets 2015 Bluestone JA, Trotta E, Xu D
• Immunotherapy: making the case for precision medicine.
  Science translational medicine 2015 Bluestone JA, Tang Q
• The immune system in Duchenne muscular dystrophy: Friend or foe.
  Rare diseases (Austin, Tex.) 2015 Villalta SA, Rosenberg AS, Bluestone JA
• The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation.
  Immunity 2015 DuPage M, Chopra G, Quiros J, Rosenthal WL, Morar MM, Holohan D, Zhang R, Turka L, Marson A, Bluestone JA
• Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability.
  Nature immunology 2015 Huynh A, DuPage M, Priyadharshini B, Sage PT, Quiros J, Borges CM, Townamchai N, Gerriets VA, Rathmell JC, Sharpe AH, Bluestone JA, Turka LA
• Innate antiviral host defense attenuates TGF-β function through IRF3-mediated suppression of Smad signaling.
  Molecular cell 2014 Xu P, Bailey-Bucktrout S, Xi Y, Xu D, Du D, Zhang Q, Xiang W, Liu J, Melton A, Sheppard D, Chapman HA, Bluestone JA, Derynck R
• Tolerance induction and reversal of diabetes in mice transplanted with human embryonic stem cell-derived pancreatic endoderm.
  Cell stem cell 2014 Szot GL, Yadav M, Lang J, Kroon E, Kerr J, Kadoya K, Brandon EP, Baetge EE, Bour-Jordan H, Bluestone JA
• Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy.
  Blood 2014 Van Gool F, Molofsky AB, Morar MM, Rosenzwajg M, Liang HE, Klatzmann D, Locksley RM, Bluestone JA
• Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy.
  Science translational medicine 2014 Villalta SA, Rosenthal W, Martinez L, Kaur A, Sparwasser T, Tidball JG, Margeta M, Spencer MJ, Bluestone JA
• Aberrant innate immune activation following tissue injury impairs pancreatic regeneration.
  PloS one 2014 Folias AE, Penaranda C, Su AL, Bluestone JA, Hebrok M
• Tyrosine 201 of the cytoplasmic tail of CTLA-4 critically affects T regulatory cell suppressive function.
  European journal of immunology 2014 Stumpf M, Zhou X, Chikuma S, Bluestone JA
• Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis.
  Nature medicine 2013 Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kodama T, Tanaka S, Bluestone JA, Takayanagi H
• Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response.
  Immunity 2013 Bailey-Bucktrout SL, Martinez-Llordella M, Zhou X, Anthony B, Rosenthal W, Luche H, Fehling HJ, Bluestone JA
• Regulatory T-cell therapy in transplantation: moving to the clinic.
  Cold Spring Harbor perspectives in medicine 2013 Tang Q, Bluestone JA
• Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation.
  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2013 Putnam AL, Safinia N, Medvec A, Laszkowska M, Wray M, Mintz MA, Trotta E, Szot GL, Liu W, Lares A, Lee K, Laing A, Lechler RI, Riley JL, Bluestone JA, Lombardi G, Tang Q
• Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial.
  The lancet. Diabetes & endocrinology 2013 Gitelman SE, Gottlieb PA, Rigby MR, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, Ding L, Bluestone JA, Ehlers MR, …
• Peripherally induced tregs - role in immune homeostasis and autoimmunity.
  Frontiers in immunology 2013 Yadav M, Stephan S, Bluestone JA
• CD28-inducible transcription factor DEC1 is required for efficient autoreactive CD4+ T cell response.
  The Journal of experimental medicine 2013 Martínez-Llordella M, Esensten JH, Bailey-Bucktrout SL, Lipsky RH, Marini A, Chen J, Mughal M, Mattson MP, Taub DD, Bluestone JA
• Production of α-galactosylceramide by a prominent member of the human gut microbiota.
  PLoS biology 2013 Wieland Brown LC, Penaranda C, Kashyap PC, Williams BB, Clardy J, Kronenberg M, Sonnenburg JL, Comstock LE, Bluestone JA, Fischbach MA
• microRNA-17-92 regulates IL-10 production by regulatory T cells and control of experimental autoimmune encephalomyelitis.
  Journal of immunology (Baltimore, Md. : 1950) 2013 de Kouchkovsky D, Esensten JH, Rosenthal WL, Morar MM, Bluestone JA, Jeker LT
• Distinct genetic control of autoimmune neuropathy and diabetes in the non-obese diabetic background.
  Journal of autoimmunity 2013 Bour-Jordan H, Thompson HL, Giampaolo JR, Davini D, Rosenthal W, Bluestone JA
• Inhibition of VEGFR-2 reverses type 1 diabetes in NOD mice by abrogating insulitis and restoring islet function.
  Diabetes 2013 Villalta SA, Lang J, Kubeck S, Kabre B, Szot GL, Calderon B, Wasserfall C, Atkinson MA, Brekken RA, Pullen N, Arch RH, Bluestone JA
• Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
  Diabetes 2013 Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA, AbATE Study Team
• The microRNA cluster miR-17∼92 promotes TFH cell differentiation and represses subset-inappropriate gene expression.
  Nature immunology 2013 Baumjohann D, Kageyama R, Clingan JM, Morar MM, Patel S, de Kouchkovsky D, Bannard O, Bluestone JA, Matloubian M, Ansel KM, Jeker LT
• DGCR8-mediated production of canonical microRNAs is critical for regulatory T cell function and stability.
  PloS one 2013 Jeker LT, Zhou X, Blelloch R, Bluestone JA
• MicroRNA regulation of T-cell differentiation and function.
  Immunological reviews 2013 Jeker LT, Bluestone JA
• Cell-based therapeutics: the next pillar of medicine.
  Science translational medicine 2013 Fischbach MA, Bluestone JA, Lim WA
• Regulatory T cells: recommendations to simplify the nomenclature.
  Nature immunology 2013 Abbas AK, Benoist C, Bluestone JA, Campbell DJ, Ghosh S, Hori S, Jiang S, Kuchroo VK, Mathis D, Roncarolo MG, Rudensky A, Sakaguchi S, Shevach EM, Vignali DA, Ziegler SF
• Type 1 diabetes: translating mechanistic observations into effective clinical outcomes.
  Nature reviews. Immunology 2013 Herold KC, Vignali DA, Cooke A, Bluestone JA
• Cutting Edge: a novel, human-specific interacting protein couples FOXP3 to a chromatin-remodeling complex that contains KAP1/TRIM28.
  Journal of immunology (Baltimore, Md. : 1950) 2013 Huang C, Martin S, Pfleger C, Du J, Buckner JH, Bluestone JA, Riley JL, Ziegler SF
• Immune therapy and β-cell death in type 1 diabetes.
  Diabetes 2013 Lebastchi J, Deng S, Lebastchi AH, Beshar I, Gitelman S, Willi S, Gottlieb P, Akirav EM, Bluestone JA, Herold KC
• The B7-independent isoform of CTLA-4 functions to regulate autoimmune diabetes.
  Journal of immunology (Baltimore, Md. : 1950) 2013 Stumpf M, Zhou X, Bluestone JA
• Current and future immunomodulation strategies to restore tolerance in autoimmune diseases.
  Cold Spring Harbor perspectives in biology 2012 Bluestone JA, Bour-Jordan H
• Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.
  Diabetologia 2012 Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA
• Altered balance between effector T cells and FOXP3+ HELIOS+ regulatory T cells after thymoglobulin induction in kidney transplant recipients.
  Transplant international : official journal of the European Society for Organ Transplantation 2012 Tang Q, Leung J, Melli K, Lay K, Chuu EL, Liu W, Bluestone JA, Kang SM, Peddi VR, Vincenti F
• Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo.
  The Journal of experimental medicine 2012 Yadav M, Louvet C, Davini D, Gardner JM, Martinez-Llordella M, Bailey-Bucktrout S, Anthony BA, Sverdrup FM, Head R, Kuster DJ, Ruminski P, Weiss D, Von Schack D, Bluestone JA
• Single step isolation and activation of primary CD3+ T lymphocytes using alcohol-dispersed electrospun magnetic nanofibers.
  Nano letters 2012 Kim K, An HJ, Jun SH, Kim TJ, Lim SA, Park G, Na HB, Park YI, Hyeon T, Yee C, Bluestone JA, Kim J, Lee KM
• The future of cancer treatment: will it include immunotherapy?
  Cancer cell 2012 Bluestone JA, Small EJ
• IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells.
  Proceedings of the National Academy of Sciences of the United States of America 2012 Penaranda C, Kuswanto W, Hofmann J, Kenefeck R, Narendran P, Walker LS, Bluestone JA, Abbas AK, Dooms H
• Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.
  Diabetes 2012 Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum …
• MicroRNA 10a marks regulatory T cells.
  PloS one 2012 Jeker LT, Zhou X, Gershberg K, de Kouchkovsky D, Morar MM, Stadthagen G, Lund AH, Bluestone JA
• NK cells are not required for spontaneous autoimmune diabetes in NOD mice.
  PloS one 2012 Beilke JN, Meagher CT, Hosiawa K, Champsaur M, Bluestone JA, Lanier LL
• A resource for the conditional ablation of microRNAs in the mouse.
  Cell reports 2012 Park CY, Jeker LT, Carver-Moore K, Oh A, Liu HJ, Cameron R, Richards H, Li Z, Adler D, Yoshinaga Y, Martinez M, Nefadov M, Abbas AK, Weiss A, Lanier LL, de Jong PJ, Bluestone JA, Srivastava D, McManus…
• Breakdown in peripheral tolerance in type 1 diabetes in mice and humans.
  Cold Spring Harbor perspectives in medicine 2012 Jeker LT, Bour-Jordan H, Bluestone JA
• CD4(+)Foxp3(+) regulatory T cell therapy in transplantation.
  Journal of molecular cell biology 2011 Tang Q, Bluestone JA, Kang SM
• The yin and yang of interleukin-2-mediated immunotherapy.
  The New England journal of medicine 2011 Bluestone JA
• A mimic of viral double-stranded RNA triggers fulminant type 1 diabetes-like syndrome in regulatory T cell-deficient autoimmune diabetic mouse.
  Journal of immunology (Baltimore, Md. : 1950) 2011 Tada A, Shimada A, Yamada T, Oikawa Y, Yamada Y, Okubo Y, Irie J, Bluestone JA, Itoh H
• Pillars article: CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994. 1: 405-413.
  Journal of immunology (Baltimore, Md. : 1950) 2011 Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA
• Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation.
  Nature immunology 2011 Beyer M, Thabet Y, Müller RU, Sadlon T, Classen S, Lahl K, Basu S, Zhou X, Bailey-Bucktrout SL, Krebs W, Schönfeld EA, Böttcher J, Golovina T, Mayer CT, Hofmann A, Sommer D, Debey-Pascher S, Endl E, …
• Type 1 diabetes immunotherapy: is the glass half empty or half full?
  Science translational medicine 2011 Herold KC, Bluestone JA
• Control of TH17 cells occurs in the small intestine.
  Nature 2011 Esplugues E, Huber S, Gagliani N, Hauser AE, Town T, Wan YY, O'Connor W, Rongvaux A, Van Rooijen N, Haberman AM, Iwakura Y, Kuchroo VK, Kolls JK, Bluestone JA, Herold KC, Flavell RA
• Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells.
  Journal of immunology (Baltimore, Md. : 1950) 2011 Penaranda C, Tang Q, Bluestone JA
• Regulatory T cells: stability revisited.
  Trends in immunology 2011 Bailey-Bucktrout SL, Bluestone JA
• Evidence that Cd101 is an autoimmune diabetes gene in nonobese diabetic mice.
  Journal of immunology (Baltimore, Md. : 1950) 2011 Rainbow DB, Moule C, Fraser HI, Clark J, Howlett SK, Burren O, Christensen M, Moody V, Steward CA, Mohammed JP, Fusakio ME, Masteller EL, Finger EB, Houchins JP, Naf D, Koentgen F, Ridgway WM, Todd JA…
• How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited.
  Diabetes 2011 Atkinson MA, Bluestone JA, Eisenbarth GS, Hebrok M, Herold KC, Accili D, Pietropaolo M, Arvan PR, Von Herrath M, Markel DS, Rhodes CJ
• Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family.
  Immunological reviews 2011 Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA
• Mechanisms of tolerance.
  Immunological reviews 2011 Bluestone JA
• Requirements for prolongation of allograft survival with regulatory T cell infusion in lymphosufficient hosts.
  The Journal of surgical research 2011 Brennan TV, Tang Q, Liu FC, Hoang V, Bi M, Bluestone JA, Kang SM
• Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes.
  Journal of immunology (Baltimore, Md. : 1950) 2011 McClymont SA, Putnam AL, Lee MR, Esensten JH, Liu W, Hulme MA, Hoffmüller U, Baron U, Olek S, Bluestone JA, Brusko TM
• Cutting edge: vasostatin-1-derived peptide ChgA29-42 is an antigenic epitope of diabetogenic BDC2.5 T cells in nonobese diabetic mice.
  Journal of immunology (Baltimore, Md. : 1950) 2011 Nikoopour E, Sandrock C, Huszarik K, Krougly O, Lee-Chan E, Masteller EL, Bluestone JA, Singh B
• Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells.
  PloS one 2011 Golovina TN, Mikheeva T, Brusko TM, Blazar BR, Bluestone JA, Riley JL
• Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade.
  Transplantation 2010 Posselt AM, Szot GL, Frassetto LA, Masharani U, Tavakol M, Amin R, McElroy J, Ramos MD, Kerlan RK, Fong L, Vincenti F, Bluestone JA, Stock PG
• Expression of αvβ8 integrin on dendritic cells regulates Th17 cell development and experimental autoimmune encephalomyelitis in mice.
  The Journal of clinical investigation 2010 Melton AC, Bailey-Bucktrout SL, Travis MA, Fife BT, Bluestone JA, Sheppard D
• The Immune Tolerance Network at 10 years: tolerance research at the bedside.
  Nature reviews. Immunology 2010 Bluestone JA, Auchincloss H, Nepom GT, Rotrosen D, St Clair EW, Turka LA
• Clusterin synergizes with IL-2 for the expansion and IFN-γ production of natural killer cells.
  Journal of leukocyte biology 2010 Sonn CH, Yu YB, Hong YJ, Shim YJ, Bluestone JA, Min BH, Lee KM
• IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells.
  The Journal of experimental medicine 2010 Grinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, Gregoire S, Cagnard N, Carpentier W, Tang Q, Bluestone J, Chatenoud L, Klatzmann D, Salomon BL, Piaggio E
• Bringing transplantation tolerance into the clinic: lessons from the ITN and RISET for the Establishment of Tolerance consortia.
  Current opinion in organ transplantation 2010 Turka LA, Wood K, Bluestone JA
• Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab.
  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2010 Posselt AM, Bellin MD, Tavakol M, Szot GL, Frassetto LA, Masharani U, Kerlan RK, Fong L, Vincenti FG, Hering BJ, Bluestone JA, Stock PG
• FK506 causes cellular and functional defects in human natural killer cells.
  Journal of leukocyte biology 2010 Kim TJ, Kim N, Kang HJ, Kim EO, Kim ST, Ahn HS, Bluestone JA, Lee KM
• Human antigen-specific regulatory T cells generated by T cell receptor gene transfer.
  PloS one 2010 Brusko TM, Koya RC, Zhu S, Lee MR, Putnam AL, McClymont SA, Nishimura MI, Han S, Chang LJ, Atkinson MA, Ribas A, Bluestone JA
• The Type 1 Diabetes PhysioLab Platform: a validated physiologically based mathematical model of pathogenesis in the non-obese diabetic mouse.
  Clinical and experimental immunology 2010 Shoda L, Kreuwel H, Gadkar K, Zheng Y, Whiting C, Atkinson M, Bluestone J, Mathis D, Young D, Ramanujan S
• Small RNA regulators of T cell-mediated autoimmunity.
  Journal of clinical immunology 2010 Jeker LT, Bluestone JA
• Genetics, pathogenesis and clinical interventions in type 1 diabetes.
  Nature 2010 Bluestone JA, Herold K, Eisenbarth G
• Suppression of human anti-porcine natural killer cell xenogeneic responses by combinations of monoclonal antibodies specific to CD2 and NKG2D and extracellular signal-regulated kinase kinase inhibitor.
  Immunology 2010 Kim TJ, Kim N, Kim EO, Choi JR, Bluestone JA, Lee KM
• Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs.
  Diabetes 2010 Penaranda C, Tang Q, Ruddle NH, Bluestone JA
• Ten years of the Immune Tolerance Network: an integrated clinical research organization.
  Science translational medicine 2010 Bluestone JA, Krensky AM, Turka LA, Rotrosen D, Matthews JB
• Regulatory T cells directed to the site of the action.
  Proceedings of the National Academy of Sciences of the United States of America 2009 Brusko TM, Bluestone JA
• Autoimmunity.
  Current opinion in immunology 2009 Bluestone JA, Kuchroo V
• Is antigen specificity of autoreactive T cells the key to islet entry?
  Immunity 2009 Penaranda C, Bluestone JA
• The functional plasticity of T cell subsets.
  Nature reviews. Immunology 2009 Bluestone JA, Mackay CR, O'Shea JJ, Stockinger B
• How suppressor cells led to anergy, costimulation, and beyond.
  Journal of immunology (Baltimore, Md. : 1950) 2009 Bour-Jordan H, Bluestone JA
• Regulatory T cells as therapeutic targets in rheumatoid arthritis.
  Nature reviews. Rheumatology 2009 Esensten JH, Wofsy D, Bluestone JA
• Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.
  Nature immunology 2009 Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, Azuma M, Krummel MF, Bluestone JA
• Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo.
  Nature immunology 2009 Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Martínez-Llordella M, Ashby M, Nakayama M, Rosenthal W, Bluestone JA
• Insulin receptor substrate-2 in beta-cells decreases diabetes in nonobese diabetic mice.
  Endocrinology 2009 Norquay LD, D'Aquino KE, Opare-Addo LM, Kuznetsova A, Haas M, Bluestone JA, White MF
• Lethal effect of CD3-specific antibody in mice deficient in TGF-beta1 by uncontrolled flu-like syndrome.
  Journal of immunology (Baltimore, Md. : 1950) 2009 Perruche S, Zhang P, Maruyama T, Bluestone JA, Saas P, Chen W
• T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function.
  Journal of immunology (Baltimore, Md. : 1950) 2009 Esensten JH, Lee MR, Glimcher LH, Bluestone JA
• Anti-CTLA-4 treatment induces IL-10-producing ICOS+ regulatory T cells displaying IDO-dependent anti-inflammatory properties in a mouse model of colitis.
  Gut 2009 Coquerelle C, Oldenhove G, Acolty V, Denoeud J, Vansanten G, Verdebout JM, Mellor A, Bluestone JA, Moser M
• Plasticity of CD4(+) FoxP3(+) T cells.
  Current opinion in immunology 2009 Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA
• Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
  Clinical immunology (Orlando, Fla.) 2009 Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA, Immune Tolerance Network ITN007AI Study Group
• Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells.
  Immunological reviews 2009 Bour-Jordan H, Bluestone JA
• A novel myelin P0-specific T cell receptor transgenic mouse develops a fulminant autoimmune peripheral neuropathy.
  The Journal of experimental medicine 2009 Louvet C, Kabre BG, Davini DW, Martinier N, Su MA, DeVoss JJ, Rosenthal WL, Anderson MS, Bour-Jordan H, Bluestone JA
• The role of X-linked FOXP3 in the autoimmune susceptibility of Turner Syndrome patients.
  Clinical immunology (Orlando, Fla.) 2009 Su MA, Stenerson M, Liu W, Putnam A, Conte F, Bluestone JA, Anderson MS
• Expansion of human regulatory T-cells from patients with type 1 diabetes.
  Diabetes 2008 Putnam AL, Brusko TM, Lee MR, Liu W, Szot GL, Ghosh T, Atkinson MA, Bluestone JA
• Immunoregulatory pathways controlling progression of autoimmunity in NOD mice.
  Annals of the New York Academy of Sciences 2008 You S, Alyanakian MA, Segovia B, Damotte D, Bluestone J, Bach JF, Chatenoud L
• Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice.
  Proceedings of the National Academy of Sciences of the United States of America 2008 Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, Zhu S, Weiss A, Bluestone JA
• The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation.
  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2008 Bluestone JA, Liu W, Yabu JM, Laszik ZG, Putnam A, Belingheri M, Gross DM, Townsend RM, Vincenti F
• Innate immunity and intestinal microbiota in the development of Type 1 diabetes.
  Nature 2008 Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, Hu C, Wong FS, Szot GL, Bluestone JA, Gordon JI, Chervonsky AV
• Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity.
  The Journal of experimental medicine 2008 Zhou X, Jeker LT, Fife BT, Zhu S, Anderson MS, McManus MT, Bluestone JA
• T regulatory cells in autoimmune diabetes: past challenges, future prospects.
  Journal of clinical immunology 2008 Bluestone JA, Tang Q, Sedwick CE
• Targeting CD22 reprograms B-cells and reverses autoimmune diabetes.
  Diabetes 2008 Fiorina P, Vergani A, Dada S, Jurewicz M, Wong M, Law K, Wu E, Tian Z, Abdi R, Guleria I, Rodig S, Dunussi-Joannopoulos K, Bluestone J, Sayegh MH
• Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
  Immunological reviews 2008 Fife BT, Bluestone JA
• Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD mice.
  Journal of immunology (Baltimore, Md. : 1950) 2008 Meagher C, Tang Q, Fife BT, Bour-Jordan H, Wu J, Pardoux C, Bi M, Melli K, Bluestone JA
• Human regulatory T cells: role in autoimmune disease and therapeutic opportunities.
  Immunological reviews 2008 Brusko TM, Putnam AL, Bluestone JA
• Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction.
  Immunity 2008 Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E, Piccirillo CA, Salomon BL, Bluestone JA
• CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells.
  Nature medicine 2008 Perruche S, Zhang P, Liu Y, Saas P, Bluestone JA, Chen W
• Clinical application of regulatory T cells for treatment of type 1 diabetes and transplantation.
  European journal of immunology 2008 Brusko T, Bluestone J
• The Foxp3+ regulatory T cell: a jack of all trades, master of regulation.
  Nature immunology 2008 Tang Q, Bluestone JA
• Safer, longer-lasting regulatory T cells with beta-catenin.
  Nature medicine 2008 Bluestone JA, Hebrok M
• Regulated beta-cell regeneration in the adult mouse pancreas.
  Diabetes 2007 Cano DA, Rulifson IC, Heiser PW, Swigart LB, Pelengaris S, German M, Evan GI, Bluestone JA, Hebrok M
• B cell depletion: a novel therapy for autoimmune diabetes?
  The Journal of clinical investigation 2007 Bour-Jordan H, Bluestone JA
• Transplantation of pancreatic islets into the kidney capsule of diabetic mice.
  Journal of visualized experiments : JoVE 2007 Szot GL, Koudria P, Bluestone JA
• Murine pancreatic islet isolation.
  Journal of visualized experiments : JoVE 2007 Szot GL, Koudria P, Bluestone JA
• Regulatory T cells: therapeutic potential for treating transplant rejection and type I diabetes.
  Journal of visualized experiments : JoVE 2007 Bluestone JA
• Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice.
  Nature 2007 Travis MA, Reizis B, Melton AC, Masteller E, Tang Q, Proctor JM, Wang Y, Bernstein X, Huang X, Reichardt LF, Bluestone JA, Sheppard D
• Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells.
  Endocrinology 2007 Sherry NA, Chen W, Kushner JA, Glandt M, Tang Q, Tsai S, Santamaria P, Bluestone JA, Brillantes AM, Herold KC
• What does the future hold for cell-based tolerogenic therapy?
  Nature reviews. Immunology 2007 Bluestone JA, Thomson AW, Shevach EM, Weiner HL
• CD3-specific antibodies: a portal to the treatment of autoimmunity.
  Nature reviews. Immunology 2007 Chatenoud L, Bluestone JA
• Constitutive expression of B7-1 on B cells uncovers autoimmunity toward the B cell compartment in the nonobese diabetic mouse.
  Journal of immunology (Baltimore, Md. : 1950) 2007 Bour-Jordan H, Salomon BL, Thompson HL, Santos R, Abbas AK, Bluestone JA
• Mechanisms of PDL1-mediated regulation of autoimmune diabetes.
  Clinical immunology (Orlando, Fla.) 2007 Guleria I, Gubbels Bupp M, Dada S, Fife B, Tang Q, Ansari MJ, Trikudanathan S, Vadivel N, Fiorina P, Yagita H, Azuma M, Atkinson M, Bluestone JA, Sayegh MH
• CD4+CD25+ regulatory T cells in transplantation: progress, challenges and prospects.
  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2007 Kang SM, Tang Q, Bluestone JA
• Expression of CTLA-4 and FOXP3 in cis protects from lethal lymphoproliferative disease.
  European journal of immunology 2007 Chikuma S, Bluestone JA
• Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment.
  Proceedings of the National Academy of Sciences of the United States of America 2007 You S, Leforban B, Garcia C, Bach JF, Bluestone JA, Chatenoud L
• New reagents on the horizon for immune tolerance.
  Annual review of medicine 2007 St Clair EW, Turka LA, Saxon A, Matthews JB, Sayegh MH, Eisenbarth GS, Bluestone J
• Sensory neurons link the nervous system and autoimmune diabetes.
  Cell 2006 Bour-Jordan H, Bluestone JA
• Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway.
  The Journal of experimental medicine 2006 Fife BT, Guleria I, Gubbels Bupp M, Eagar TN, Tang Q, Bour-Jordan H, Yagita H, Azuma M, Sayegh MH, Bluestone JA
• International trial of the Edmonton protocol for islet transplantation.
  The New England journal of medicine 2006 Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, Secchi A, Brendel MD, Berney T, Brennan DC, Cagliero E, Alejandro R, Ryan EA, DiMercurio B, Morel P, Polonsky KS, Reems JA, …
• Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study.
  Diabetes 2006 Seyfert-Margolis V, Gisler TD, Asare AL, Wang RS, Dosch HM, Brooks-Worrell B, Eisenbarth GS, Palmer JP, Greenbaum CJ, Gitelman SE, Nepom GT, Bluestone JA, Herold KC
• Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist.
  The Journal of clinical investigation 2006 Fife BT, Griffin MD, Abbas AK, Locksley RM, Bluestone JA
• Regulatory T-cell physiology and application to treat autoimmunity.
  Immunological reviews 2006 Tang Q, Bluestone JA
• Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells.
  Journal of immunology (Baltimore, Md. : 1950) 2006 Scalapino KJ, Tang Q, Bluestone JA, Bonyhadi ML, Daikh DI
• CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells.
  The Journal of experimental medicine 2006 Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA
• Plasmacytoid DCs and T(reg) cells: casual acquaintance or monogamous relationship?
  Nature immunology 2006 Tang Q, Bluestone JA
• Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs.
  The Journal of clinical investigation 2006 Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, Herold KC, von Herrath M
• CTLA4Ig: bridging the basic immunology with clinical application.
  Immunity 2006 Bluestone JA, St Clair EW, Turka LA
• Antigen-specific regulatory T cells--ex vivo expansion and therapeutic potential.
  Seminars in immunology 2006 Masteller EL, Tang Q, Bluestone JA
• Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice.
  Nature immunology 2005 Tang Q, Adams JY, Tooley AJ, Bi M, Fife BT, Serra P, Santamaria P, Locksley RM, Krummel MF, Bluestone JA
• Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen.
  The Journal of experimental medicine 2005 Knoechel B, Lohr J, Kahn E, Bluestone JA, Abbas AK
• Distinct effector mechanisms in the development of autoimmune neuropathy versus diabetes in nonobese diabetic mice.
  Journal of immunology (Baltimore, Md. : 1950) 2005 Bour-Jordan H, Thompson HL, Bluestone JA
• How do CD4+CD25+ regulatory T cells control autoimmunity?
  Current opinion in immunology 2005 Bluestone JA, Tang Q
• A peptide of glutamic acid decarboxylase 65 can recruit and expand a diabetogenic T cell clone, BDC2.5, in the pancreas.
  Journal of immunology (Baltimore, Md. : 1950) 2005 Dai YD, Jensen KP, Lehuen A, Masteller EL, Bluestone JA, Wilson DB, Sercarz EE
• TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs.
  The Journal of clinical investigation 2005 Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC
• Achieving antigen-specific tolerance in diabetes: regulating specifically.
  International reviews of immunology 2005 Chen W, Bluestone JA, Herold KC
• Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice.
  Journal of immunology (Baltimore, Md. : 1950) 2005 Masteller EL, Warner MR, Tang Q, Tarbell KV, McDevitt H, Bluestone JA
• A comprehensive review of interventions in the NOD mouse and implications for translation.
  Immunity 2005 Shoda LK, Young DL, Ramanujan S, Whiting CC, Atkinson MA, Bluestone JA, Eisenbarth GS, Mathis D, Rossini AA, Campbell SE, Kahn R, Kreuwel HT
• B7-independent inhibition of T cells by CTLA-4.
  Journal of immunology (Baltimore, Md. : 1950) 2005 Chikuma S, Abbas AK, Bluestone JA
• A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.
  Diabetes 2005 Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA
• An important role of CD80/CD86-CTLA-4 signaling during photocarcinogenesis in mice.
  Journal of immunology (Baltimore, Md. : 1950) 2005 Loser K, Scherer A, Krummen MB, Varga G, Higuchi T, Schwarz T, Sharpe AH, Grabbe S, Bluestone JA, Beissert S
• Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo.
  Journal of immunology (Baltimore, Md. : 1950) 2005 Bezbradica JS, Stanic AK, Matsuki N, Bour-Jordan H, Bluestone JA, Thomas JW, Unutmaz D, Van Kaer L, Joyce S
• Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis.
  Journal of immunology (Baltimore, Md. : 1950) 2005 Kohm AP, Williams JS, Bickford AL, McMahon JS, Chatenoud L, Bach JF, Bluestone JA, Miller SD
• In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation.
  Clinical immunology (Orlando, Fla.) 2005 Earle KE, Tang Q, Zhou X, Liu W, Zhu S, Bonyhadi ML, Bluestone JA
• Regulatory T-cell therapy: is it ready for the clinic?
  Nature reviews. Immunology 2005 Bluestone JA
• CTLA-4Ig is finally making it: a personal perspective.
  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2005 Bluestone JA
• Differential roles of costimulatory signaling pathways in type 1 diabetes mellitus.
  The review of diabetic studies : RDS 2005 Boehm BO, Bluestone JA
• The NOD mouse: a model of immune dysregulation.
  Annual review of immunology 2005 Anderson MS, Bluestone JA
• Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function.
  European journal of immunology 2004 Tang Q, Boden EK, Henriksen KJ, Bour-Jordan H, Bi M, Bluestone JA
• Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells.
  The Journal of clinical investigation 2004 Bour-Jordan H, Salomon BL, Thompson HL, Szot GL, Bernhard MR, Bluestone JA
• Peptide specific amelioration of T cell mediated pathogenesis in murine type 1 diabetes.
  Clinical immunology (Orlando, Fla.) 2004 Judkowski V, Rodriguez E, Pinilla C, Masteller E, Bluestone JA, Sarvetnick N, Wilson DB
• Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells.
  Proceedings of the National Academy of Sciences of the United States of America 2004 Bluestone JA, Tang Q
• CTLA-4 regulates expansion and differentiation of Th1 cells following induction of peripheral T cell tolerance.
  Journal of immunology (Baltimore, Md. : 1950) 2004 Eagar TN, Turley DM, Padilla J, Karandikar NJ, Tan L, Bluestone JA, Miller SD
• In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes.
  The Journal of experimental medicine 2004 Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, Masteller EL, McDevitt H, Bonyhadi M, Bluestone JA
• NKG2D blockade prevents autoimmune diabetes in NOD mice.
  Immunity 2004 Ogasawara K, Hamerman JA, Ehrlich LR, Bour-Jordan H, Santamaria P, Bluestone JA, Lanier LL
• Notch signaling in lymphocyte development and function.
  Current opinion in immunology 2004 Robey EA, Bluestone JA
• Notch 1 signaling regulates peripheral T cell activation.
  Immunity 2004 Eagar TN, Tang Q, Wolfe M, He Y, Pear WS, Bluestone JA
• Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody.
  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2004 Hering BJ, Kandaswamy R, Harmon JV, Ansite JD, Clemmings SM, Sakai T, Paraskevas S, Eckman PM, Sageshima J, Nakano M, Sawada T, Matsumoto I, Zhang HJ, Sutherland DE, Bluestone JA
• Importance of IL-10 for CTLA-4-mediated inhibition of tumor-eradicating immunity.
  Journal of immunology (Baltimore, Md. : 1950) 2004 Jovasevic VM, Gorelik L, Bluestone JA, Mokyr MB
• Insulin secretion in type 1 diabetes.
  Diabetes 2004 Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI, Donaldson D, Harlan DM, Bluestone J, Herold KC
• Beta-cell replacement for type I diabetes.
  Annual review of medicine 2004 Stock PG, Bluestone JA
• Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes.
  Journal of immunology (Baltimore, Md. : 1950) 2003 Masteller EL, Warner MR, Ferlin W, Judkowski V, Wilson D, Glaichenhaus N, Bluestone JA
• Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells.
  Journal of immunology (Baltimore, Md. : 1950) 2003 Tang Q, Henriksen KJ, Boden EK, Tooley AJ, Ye J, Subudhi SK, Zheng XX, Strom TB, Bluestone JA
• TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes.
  Nature medicine 2003 Belghith M, Bluestone JA, Barriot S, Mégret J, Bach JF, Chatenoud L
• Targeting and blocking B7 costimulatory molecules on antigen-presenting cells using CTLA4Ig-conjugated liposomes: in vitro characterization and in vivo factors affecting biodistribution.
  Pharmaceutical research 2003 Park CG, Thiex NW, Lee KM, Szot GL, Bluestone JA, Lee KD
• Clinical trials of transplant tolerance: slow but steady progress.
  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2003 Matthews JB, Ramos E, Bluestone JA
• Altered cutaneous immune parameters in transgenic mice overexpressing viral IL-10 in the epidermis.
  The Journal of clinical investigation 2003 Ding W, Beissert S, Deng L, Miranda E, Cassetty C, Seiffert K, Campton KL, Yan Z, Murphy GF, Bluestone JA, Granstein RD
• Natural versus adaptive regulatory T cells.
  Nature reviews. Immunology 2003 Bluestone JA, Abbas AK
• Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).
  The Journal of clinical investigation 2003 Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone JA
• CD28/B7 regulation of anti-CD3-mediated immunosuppression in vivo.
  Journal of immunology (Baltimore, Md. : 1950) 2003 Tang Q, Smith JA, Szot GL, Zhou P, Alegre ML, Henriksen KJ, Thompson CB, Bluestone JA
• Directed evolution of a single-chain class II MHC product by yeast display.
  Protein engineering 2003 Starwalt SE, Masteller EL, Bluestone JA, Kranz DM
• CTLA-4 regulates the requirement for cytokine-induced signals in T(H)2 lineage commitment.
  Nature immunology 2003 Bour-Jordan H, Grogan JL, Tang Q, Auger JA, Locksley RM, Bluestone JA
• Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4.
  The Journal of experimental medicine 2003 Chikuma S, Imboden JB, Bluestone JA
• CTLA-4 and tolerance: the biochemical point of view.
  Immunologic research 2003 Chikuma S, Bluestone JA
• Impairment of NK cell function by NKG2D modulation in NOD mice.
  Immunity 2003 Ogasawara K, Hamerman JA, Hsin H, Chikuma S, Bour-Jordan H, Chen T, Pertel T, Carnaud C, Bluestone JA, Lanier LL
• The role of CD28 and CTLA4 in the function and homeostasis of CD4+CD25+ regulatory T cells.
  Novartis Foundation symposium 2003 Boden E, Tang Q, Bour-Jordan H, Bluestone JA
• When ligand becomes receptor--tolerance via B7 signaling on DCs.
  Nature immunology 2002 Finger EB, Bluestone JA
• Immunotherapy of insulin-dependent diabetes mellitus.
  Current opinion in immunology 2002 Masteller EL, Bluestone JA
• Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial.
  The Journal of rheumatology 2002 Utset TO, Auger JA, Peace D, Zivin RA, Xu D, Jolliffe L, Alegre ML, Bluestone JA, Clark MR
• Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells.
  Journal of immunology (Baltimore, Md. : 1950) 2002 Hwang KW, Sweatt WB, Brown IE, Blank C, Gajewski TF, Bluestone JA, Alegre ML
• CTLA-4: acting at the synapse.
  Molecular interventions 2002 Chikuma S, Bluestone JA
• Inability to induce tolerance through direct antigen presentation.
  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2002 Rulifson IC, Szot GL, Palmer E, Bluestone JA
• The immune tolerance network: a new paradigm for developing tolerance-inducing therapies.
  The Journal of allergy and clinical immunology 2002 Rotrosen D, Matthews JB, Bluestone JA
• Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.
  The New England journal of medicine 2002 Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA
• The Src family kinase Fyn mediates signals induced by TCR antagonists.
  Journal of immunology (Baltimore, Md. : 1950) 2002 Tang Q, Subudhi SK, Henriksen KJ, Long CG, Vives F, Bluestone JA
• The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance.
  European journal of immunology 2002 Eagar TN, Karandikar NJ, Bluestone JA, Miller SD
• Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice.
  The Journal of experimental medicine 2001 Salomon B, Rhee L, Bour-Jordan H, Hsin H, Montag A, Soliven B, Arcella J, Girvin AM, Padilla J, Miller SD, Bluestone JA
• Antigen-specific blockade of T cells in vivo using dimeric MHC peptide.
  Journal of immunology (Baltimore, Md. : 1950) 2001 O'Herrin SM, Slansky JE, Tang Q, Markiewicz MA, Gajewski TF, Pardoll DM, Schneck JP, Bluestone JA
• Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy.
  The Journal of clinical investigation 2001 Wells AD, Walsh MC, Bluestone JA, Turka LA
• Suppressor T cells--they're back and critical for regulation of autoimmunity!
  Immunological reviews 2001 Chatenoud L, Salomon B, Bluestone JA
• ICOS costimulation: It's not just for TH2 cells anymore.
  Nature immunology 2001 Sperling AI, Bluestone JA
• Mechanism of melphalan-induced B7-1 gene expression in P815 tumor cells.
  Journal of immunology (Baltimore, Md. : 1950) 2001 Donepudi M, Raychaudhuri P, Bluestone JA, Mokyr MB
• The Immune Tolerance Network: tolerance at the crossroads.
  Philosophical transactions of the Royal Society of London. Series B, Biological sciences 2001 Bluestone JA, Matthews J
• Different mechanisms of cardiac allograft rejection in wildtype and CD28-deficient mice.
  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2001 Szot GL, Zhou P, Rulifson I, Wang J, Guo Z, Kim O, Newel KA, Thistlethwaite JR, Bluestone JA, Alegre ML
• Development and applications of surface-linked single chain antibodies against T-cell antigens.
  Journal of immunological methods 2001 Griffin MD, Holman PO, Tang Q, Ashourian N, Korthäuer U, Kranz DM, Bluestone JA
• Role of STAT6 signaling in the induction and long-term maintenance of tolerance mediated by CTLA4-Ig.
  Transplantation proceedings 2001 Zhou P, Szot G, Guo Z, Kim O, He G, Wang J, Grusby M, Newell K, Thistlethwaite J, Bluestone J, Alegre M
• Transplantation and the CD28/CTLA4/B7 pathway.
  Transplantation proceedings 2001 Alegre M, Fallarino F, Zhou P, Frauwirth K, Thistlethwaite J, Newell K, Gajewski T, Bluestone J
• Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation.
  Annual review of immunology 2001 Salomon B, Bluestone JA
• Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated tolerance.
  Journal of immunology (Baltimore, Md. : 1950) 2000 Zhou P, Szot GL, Guo Z, Kim O, He G, Wang J, Grusby MJ, Newell KA, Thistlethwaite JR, Bluestone JA, Alegre ML
• The immune tolerance network: the "Holy Grail" comes to the clinic.
  Journal of the American Society of Nephrology : JASN 2000 Bluestone JA, Matthews JB, Krensky AM
• CTLA-4 downregulates epitope spreading and mediates remission in relapsing experimental autoimmune encephalomyelitis.
  Journal of neuroimmunology 2000 Karandikar NJ, Eagar TN, Vanderlugt CL, Bluestone JA, Miller SD
• CD28 costimulatory blockade exacerbates disease severity and accelerates epitope spreading in a virus-induced autoimmune disease.
  Journal of virology 2000 Neville KL, Dal Canto MC, Bluestone JA, Miller SD
• The immune tolerance network--an NIH/JDF-supported initiative to bring tolerance research into the clinic: a major new resource for clinical immunologists.
  Clinical immunology (Orlando, Fla.) 2000 Bluestone JA, Matthews JB
• Evidence for functional relevance of CTLA-4 in ultraviolet-radiation-induced tolerance.
  Journal of immunology (Baltimore, Md. : 1950) 2000 Schwarz A, Beissert S, Grosse-Heitmeyer K, Gunzer M, Bluestone JA, Grabbe S, Schwarz T
• Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells.
  Journal of immunology (Baltimore, Md. : 1950) 2000 Sojka DK, Donepudi M, Bluestone JA, Mokyr MB
• Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152).
  Journal of immunology (Baltimore, Md. : 1950) 2000 Griffin MD, Hong DK, Holman PO, Lee KM, Whitters MJ, O'Herrin SM, Fallarino F, Collins M, Segal DM, Gajewski TF, Kranz DM, Bluestone JA
• B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes.
  Immunity 2000 Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA
• Absence of host B7 expression is sufficient for long-term murine vascularized heart allograft survival.
  Transplantation 2000 Szot GL, Zhou P, Sharpe AH, He G, Kim O, Newell KA, Bluestone JA, Thistlethwaite JR
• In vitro characterization of five humanized OKT3 effector function variant antibodies.
  Cellular immunology 2000 Xu D, Alegre ML, Varga SS, Rothermel AL, Collins AM, Pulito VL, Hanna LS, Dolan KP, Parren PW, Bluestone JA, Jolliffe LK, Zivin RA
• Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis.
  Journal of immunology (Baltimore, Md. : 1950) 2000 Vanderlugt CL, Neville KL, Nikcevich KM, Eagar TN, Bluestone JA, Miller SD
• A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: a comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade.
  Journal of immunology (Baltimore, Md. : 1950) 2000 Girvin AM, Dal Canto MC, Rhee L, Salomon B, Sharpe A, Bluestone JA, Miller SD
• Anergic T lymphocytes selectively express an integrin regulatory protein of the cytohesin family.
  Journal of immunology (Baltimore, Md. : 1950) 2000 Korthäuer U, Nagel W, Davis EM, Le Beau MM, Menon RS, Mitchell EO, Kozak CA, Kolanus W, Bluestone JA
• Reduced ultraviolet-induced carcinogenesis in mice with a functional disruption in B7-mediated costimulation.
  Journal of immunology (Baltimore, Md. : 1950) 1999 Beissert S, Bluestone JA, Mindt I, Voskort M, Metze D, Mehling A, Luger TA, Schwarz T, Grabbe S
• RIBP, a novel Rlk/Txk- and itk-binding adaptor protein that regulates T cell activation.
  The Journal of experimental medicine 1999 Rajagopal K, Sommers CL, Decker DC, Mitchell EO, Korthauer U, Sperling AI, Kozak CA, Love PE, Bluestone JA
• CD28 interactions with either CD80 or CD86 are sufficient to induce allergic airway inflammation in mice.
  American journal of respiratory cell and molecular biology 1999 Mathur M, Herrmann K, Qin Y, Gulmen F, Li X, Krimins R, Weinstock J, Elliott D, Bluestone JA, Padrid P
• Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection.
  Transplantation 1999 Woodle ES, Xu D, Zivin RA, Auger J, Charette J, O'Laughlin R, Peace D, Jollife LK, Haverty T, Bluestone JA, Thistlethwaite JR
• Cutting edge: blockade of the CD28/B7 costimulatory pathway inhibits intestinal allograft rejection mediated by CD4+ but not CD8+ T cells.
  Journal of immunology (Baltimore, Md. : 1950) 1999 Newell KA, He G, Guo Z, Kim O, Szot GL, Rulifson I, Zhou P, Hart J, Thistlethwaite JR, Bluestone JA
• Induction, maintenance, and reversal of streptozotocin-induced insulin-dependent diabetes mellitus in the juvenile cynomolgus monkey (Macaca fascilularis).
  Transplantation 1999 Theriault BR, Thistlethwaite JR, Levisetti MG, Wardrip CL, Szot G, Bruce DS, Rilo H, Li X, Gray GS, Bluestone JA, Padrid PA
• Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses.
  Journal of immunology (Baltimore, Md. : 1950) 1999 Khattri R, Auger JA, Griffin MD, Sharpe AH, Bluestone JA
• Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4.
  Cancer research 1999 Richards J, Auger J, Peace D, Gale D, Michel J, Koons A, Haverty T, Zivin R, Jolliffe L, Bluestone JA
• Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism.
  Journal of immunology (Baltimore, Md. : 1950) 1999 La Motte RN, Sharpe AH, Bluestone JA, Mokyr MB
• CD2 and CD3 receptor-mediated tolerance: constraints on T cell activation.
  Transplantation 1999 Punch JD, Lin J, Bluestone J, Bromberg JS
• TCRgammadelta cells and viruses.
  Microbes and infection 1999 Sciammas R, Bluestone JA
• Activation and peripheral expansion of murine T-cell receptor gamma delta intraepithelial lymphocytes.
  Gastroenterology 1999 Guehler SR, Bluestone JA, Barrett TA
• Regulation of cytotoxic T lymphocyte-associated molecule-4 by Src kinases.
  Journal of immunology (Baltimore, Md. : 1950) 1999 Chuang E, Lee KM, Robbins MD, Duerr JM, Alegre ML, Hambor JE, Neveu MJ, Bluestone JA, Thompson CB
• The CTLA-4 gene is expressed in placental fibroblasts.
  Molecular human reproduction 1999 Kaufman KA, Bowen JA, Tsai AF, Bluestone JA, Hunt JS, Ober C
• Molecular basis of T cell inactivation by CTLA-4.
  Science (New York, N.Y.) 1998 Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, Straus D, Samelson LE, Thompson CB, Bluestone JA
• Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells.
  Journal of immunology (Baltimore, Md. : 1950) 1998 La Motte RN, Sharpe AH, Bluestone JA, Mokyr MB
• Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice.
  Cancer research 1998 Mokyr MB, Kalinichenko T, Gorelik L, Bluestone JA
• HSV-1 glycoprotein I-reactive TCR gamma delta cells directly recognize the peptide backbone in a conformationally dependent manner.
  Journal of immunology (Baltimore, Md. : 1950) 1998 Sciammas R, Bluestone JA
• LFA-1 interaction with ICAM-1 and ICAM-2 regulates Th2 cytokine production.
  Journal of immunology (Baltimore, Md. : 1950) 1998 Salomon B, Bluestone JA
• Signalling through the TCR.
  Research in immunology 1998 Cantrell D, Bluestone J, Vivier E, Tybulewicz V
• Cell fate in the immune system: decisions, decisions, decisions.
  Immunological reviews 1998 Bluestone JA
• Targeting the B7/CD28:CTLA-4 costimulatory system in CNS autoimmune disease.
  Journal of neuroimmunology 1998 Karandikar NJ, Vanderlugt CL, Bluestone JA, Miller SD
• Inhibition of collagen-induced arthritis in mice by viral IL-10 gene transfer.
  Journal of immunology (Baltimore, Md. : 1950) 1998 Ma Y, Thornton S, Duwel LE, Boivin GP, Giannini EH, Leiden JM, Bluestone JA, Hirsch R
• The functional significance of epitope spreading and its regulation by co-stimulatory molecules.
  Immunological reviews 1998 Vanderlugt CL, Begolka WS, Neville KL, Katz-Levy Y, Howard LM, Eagar TN, Bluestone JA, Miller SD
• Tissue-specific up-regulation of B7-1 expression and function during the course of murine relapsing experimental autoimmune encephalomyelitis.
  Journal of immunology (Baltimore, Md. : 1950) 1998 Karandikar NJ, Vanderlugt CL, Eagar T, Tan L, Bluestone JA, Miller SD
• Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): initial clinical experience.
  Transplantation proceedings 1998 Woodle ES, Bluestone JA, Zivin RA, Jolliffe LK, Auger J, Xu D, Thistlethwaite JR
• Increased threshold for TCR-mediated signaling controls self reactivity of intraepithelial lymphocytes.
  Journal of immunology (Baltimore, Md. : 1950) 1998 Guehler SR, Finch RJ, Bluestone JA, Barrett TA
• Dissociation of intracellular signaling pathways in response to partial agonist ligands of the T cell receptor.
  The Journal of experimental medicine 1998 Chau LA, Bluestone JA, Madrenas J
• Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets.
  Journal of immunology (Baltimore, Md. : 1950) 1998 Smith JA, Tang Q, Bluestone JA
• CTLA-4 regulates tolerance induction and T cell differentiation in vivo.
  Journal of immunology (Baltimore, Md. : 1950) 1998 Walunas TL, Bluestone JA
• CTLA4Ig inhibits airway eosinophilia and hyperresponsiveness by regulating the development of Th1/Th2 subsets in a murine model of asthma.
  American journal of respiratory cell and molecular biology 1998 Padrid PA, Mathur M, Li X, Herrmann K, Qin Y, Cattamanchi A, Weinstock J, Elliott D, Sperling AI, Bluestone JA
• Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor.
  Journal of immunology (Baltimore, Md. : 1950) 1998 Mokyr MB, Kalinichenko TV, Gorelik L, Bluestone JA
• Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation.
  Journal of immunology (Baltimore, Md. : 1950) 1997 Levisetti MG, Padrid PA, Szot GL, Mittal N, Meehan SM, Wardrip CL, Gray GS, Bruce DS, Thistlethwaite JR, Bluestone JA
• Regulation of C-C chemokine production by murine T cells by CD28/B7 costimulation.
  Journal of immunology (Baltimore, Md. : 1950) 1997 Herold KC, Lu J, Rulifson I, Vezys V, Taub D, Grusby MJ, Bluestone JA
• Treatment with intact anti-B7-1 mAb during disease remission enhances epitope spreading and exacerbates relapses in R-EAE.
  Journal of neuroimmunology 1997 Vanderlugt CL, Karandikar NJ, Lenschow DJ, Dal Canto MC, Bluestone JA, Miller SD
• T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs.
  Current opinion in immunology 1997 Smith JA, Bluestone JA
• Transplantation tolerance--putting the pieces together.
  Current opinion in immunology 1997 Lechler R, Bluestone JA
• Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.
  Cancer research 1997 Yang YF, Zou JP, Mu J, Wijesuriya R, Ono S, Walunas T, Bluestone J, Fujiwara H, Hamaoka T
• Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy.
  The Journal of experimental medicine 1997 Wick M, Dubey P, Koeppen H, Siegel CT, Fields PE, Chen L, Bluestone JA, Schreiber H
• Selective expansion of Vgamma2-Vdelta7 TCR gammadelta cells in C57BL/6 mice is postnatal and extrathymic.
  Journal of immunology (Baltimore, Md. : 1950) 1997 Sperling AI, Decker DC, DiPaolo RJ, Stern DA, Shum A, Bluestone JA
• T cell receptor-gamma/delta cells protect mice from herpes simplex virus type 1-induced lethal encephalitis.
  The Journal of experimental medicine 1997 Sciammas R, Kodukula P, Tang Q, Hendricks RL, Bluestone JA
• Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy.
  The Journal of experimental medicine 1997 Smith JA, Tso JY, Clark MR, Cole MS, Bluestone JA
• Anti-human class I MHC antibodies induce apoptosis by a pathway that is distinct from the Fas antigen-mediated pathway.
  Journal of immunology (Baltimore, Md. : 1950) 1997 Woodle ES, Smith DM, Bluestone JA, Kirkman WM, Green DR, Skowronski EW
• Is CTLA-4 a master switch for peripheral T cell tolerance?
  Journal of immunology (Baltimore, Md. : 1950) 1997 Bluestone JA
• CD28/B7 regulation of autoimmune diabetes.
  Immunologic research 1997 Herold KG, Lenschow DJ, Bluestone JA
• Class I MHC mediates programmed cell death in a Fas-independent manner.
  Transplantation proceedings 1997 Woodle ES, Smith DM, Bluestone JA, Green DR, Skowronski EW
• The efficiency of CD4 recruitment to ligand-engaged TCR controls the agonist/partial agonist properties of peptide-MHC molecule ligands.
  The Journal of experimental medicine 1997 Madrenas J, Chau LA, Smith J, Bluestone JA, Germain RN
• CD28 costimulation promotes the production of Th2 cytokines.
  Journal of immunology (Baltimore, Md. : 1950) 1997 Rulifson IC, Sperling AI, Fields PE, Fitch FW, Bluestone JA
• CD28/B7 costimulation regulates autoimmune diabetes induced with multiple low doses of streptozotocin.
  Journal of immunology (Baltimore, Md. : 1950) 1997 Herold KC, Vezys V, Koons A, Lenschow D, Thompson C, Bluestone JA
• CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation.
  Journal of immunology (Baltimore, Md. : 1950) 1996 Sperling AI, Auger JA, Ehst BD, Rulifson IC, Thompson CB, Bluestone JA
• The complexities of T-cell co-stimulation: CD28 and beyond.
  Immunological reviews 1996 Sperling AI, Bluestone JA
• TCR-gamma delta cells in CD3 zeta-deficient mice contain Fc epsilon RI gamma in the receptor complex but are specifically unresponsive to antigen.
  Journal of immunology (Baltimore, Md. : 1950) 1996 Khattri R, Sperling AI, Qian D, Fitch FW, Shores EW, Love PE, Bluestone JA
• CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes.
  Immunity 1996 Lenschow DJ, Herold KC, Rhee L, Patel B, Koons A, Qin HY, Fuchs E, Singh B, Thompson CB, Bluestone JA
• CTLA-4: a negative regulator of autoimmune disease.
  The Journal of experimental medicine 1996 Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA
• Immune deviation of 2C transgenic intraepithelial lymphocytes in antigen-bearing hosts.
  The Journal of experimental medicine 1996 Guehler SR, Bluestone JA, Barrett TA
• CTLA-4 ligation blocks CD28-dependent T cell activation.
  The Journal of experimental medicine 1996 Walunas TL, Bakker CY, Bluestone JA
• Regulation of CTLA-4 expression during T cell activation.
  Journal of immunology (Baltimore, Md. : 1950) 1996 Perkins D, Wang Z, Donovan C, He H, Mark D, Guan G, Wang Y, Walunas T, Bluestone J, Listman J, Finn PW
• Murine gamma/delta-expressing T cells affect alloengraftment via the recognition of nonclassical major histocompatibility complex class Ib antigens.
  Blood 1996 Blazar BR, Taylor PA, Bluestone JA, Vallera DA
• In vivo administration of anti-murine CD3 monoclonal antibody induces selective, long-term anergy in CD8+ T cells.
  Transplantation 1996 Woodle ES, Hussein S, Bluestone JA
• Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule.
  Cancer immunology, immunotherapy : CII 1996 La Motte RN, Rubin MA, Barr E, Leiden JM, Bluestone JA, Mokyr MB
• CD28 expression is not essential for positive and negative selection of thymocytes or peripheral T cell tolerance.
  Journal of immunology (Baltimore, Md. : 1950) 1996 Walunas TL, Sperling AI, Khattri R, Thompson CB, Bluestone JA
• Costimulation and its role in organ transplantation.
  Clinical transplantation 1996 Bluestone JA
• IL-15 is a novel growth factor for murine gamma delta T cells induced by Salmonella infection.
  Journal of immunology (Baltimore, Md. : 1950) 1996 Nishimura H, Hiromatsu K, Kobayashi N, Grabstein KH, Paxton R, Sugamura K, Bluestone JA, Yoshikai Y
• Lethal murine graft-versus-host disease induced by donor gamma/delta expressing T cells with specificity for host nonclassical major histocompatibility complex class Ib antigens.
  Blood 1996 Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Barrett TA, Bluestone JA, Vallera DA
• CD28/B7 system of T cell costimulation.
  Annual review of immunology 1996 Lenschow DJ, Walunas TL, Bluestone JA
• Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE.
  Immunity 1995 Miller SD, Vanderlugt CL, Lenschow DJ, Pope JG, Karandikar NJ, Dal Canto MC, Bluestone JA
• Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies.
  Transplantation 1995 Lenschow DJ, Zeng Y, Hathcock KS, Zuckerman LA, Freeman G, Thistlethwaite JR, Gray GS, Hodes RJ, Bluestone JA
• Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
  Immunity 1995 Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH
• Development of TCR gamma delta iIELs.
  Seminars in immunology 1995 Barrett TA, Bluestone JA
• Transplantation.
  Current opinion in immunology 1995 Bluestone JA, Lechler RI
• Functional expression and recognition of nonclassical MHC class I T10b is not peptide-dependent.
  Journal of immunology (Baltimore, Md. : 1950) 1995 Kaliyaperumal A, Falchetto R, Cox A, Dick R, Shabanowitz J, Chien YH, Matis L, Hunt DF, Bluestone JA
• Ly-6C is a marker of memory CD8+ T cells.
  Journal of immunology (Baltimore, Md. : 1950) 1995 Walunas TL, Bruce DS, Dustin L, Loh DY, Bluestone JA
• An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity.
  Journal of immunology (Baltimore, Md. : 1950) 1995 Alegre ML, Tso JY, Sattar HA, Smith J, Desalle F, Cole M, Bluestone JA
• Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4.
  Journal of immunology (Baltimore, Md. : 1950) 1995 Kearney ER, Walunas TL, Karr RW, Morton PA, Loh DY, Bluestone JA, Jenkins MK
• CD43 is a murine T cell costimulatory receptor that functions independently of CD28.
  The Journal of experimental medicine 1995 Sperling AI, Green JM, Mosley RL, Smith PL, DiPaolo RJ, Klein JR, Bluestone JA, Thompson CB
• Two waves of gamma delta T cells expressing different V delta genes are recruited into schistosome-induced liver granulomas.
  Journal of immunology (Baltimore, Md. : 1950) 1995 Sandor M, Sperling AI, Cook GA, Weinstock JV, Lynch RG, Bluestone JA
• New perspectives of CD28-B7-mediated T cell costimulation.
  Immunity 1995 Bluestone JA
• T cell costimulation through the CD28 receptor.
  Proceedings of the Association of American Physicians 1995 Green JM, Noel PJ, Sperling AI, Walunas TL, Lenschow DJ, Stack R, Gray GS, Bluestone JA, Thompson CB
• Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse.
  The Journal of experimental medicine 1995 Lenschow DJ, Ho SC, Sattar H, Rhee L, Gray G, Nabavi N, Herold KC, Bluestone JA
• Inhibition of T-cell activation by an anti-human class I MHC reactive monoclonal antibody occurs at a point distal to TCR-CD3 mediated signal transduction.
  Transplantation proceedings 1995 Smith DM, Bluestone JA, Thistlethwaite JR, Woodle ES
• Identification of Rlk, a novel protein tyrosine kinase with predominant expression in the T cell lineage.
  The Journal of biological chemistry 1995 Hu Q, Davidson D, Schwartzberg PL, Macchiarini F, Lenardo MJ, Bluestone JA, Matis LA
• Programmed differentiation of murine thymocytes during fetal thymus organ culture.
  Journal of immunological methods 1995 DeLuca D, Bluestone JA, Shultz LD, Sharrow SO, Tatsumi Y
• Immunomodulation of transplant rejection using monoclonal antibodies and soluble receptors.
  Digestive diseases and sciences 1995 Alegre ML, Lenschow DJ, Bluestone JA
• TCR gamma delta cells: a specialized T-cell subset in the immune system.
  Annual review of cell and developmental biology 1995 Bluestone JA, Khattri R, Sciammas R, Sperling AI
• Insight into the mechanism of TCR-V beta 8+/CD8+ T cell-mediated MOPC-315 tumor eradication.
  Journal of immunology (Baltimore, Md. : 1950) 1994 Mokyr MB, Prokhorova A, Rubin M, Bluestone JA
• Inhibition of transplant rejection by pretreatment of xenogeneic pancreatic islet cells with anti-ICAM-1 antibodies.
  Transplantation 1994 Zeng Y, Gage A, Montag A, Rothlein R, Thistlethwaite JR, Bluestone JA
• Severe combined immunodeficient mice engrafted with human splenocytes have functional human T cells and reject human allografts.
  Journal of immunology (Baltimore, Md. : 1950) 1994 Alegre ML, Peterson LJ, Jeyarajah DR, Weiser M, Bluestone JA, Thistlethwaite JR
• Absence of B7-dependent responses in CD28-deficient mice.
  Immunity 1994 Green JM, Noel PJ, Sperling AI, Walunas TL, Gray GS, Bluestone JA, Thompson CB
• Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen.
  Journal of immunology (Baltimore, Md. : 1950) 1994 Lenschow DJ, Sperling AI, Cooke MP, Freeman G, Rhee L, Decker DC, Gray G, Nadler LM, Goodnow CC, Bluestone JA
• CTLA-4 can function as a negative regulator of T cell activation.
  Immunity 1994 Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA
• Inhibition of T cell activation by a monoclonal antibody reactive against the alpha 3 domain of human MHC class I molecules.
  Journal of immunology (Baltimore, Md. : 1950) 1994 Smith DM, Bluestone JA, Jeyarajah DR, Newberg MH, Engelhard VH, Thistlethwaite JR, Woodle ES
• The B7 and CD28 receptor families.
  Immunology today 1994 June CH, Bluestone JA, Nadler LM, Thompson CB
• Prevention of the humoral response induced by an anti-CD3 monoclonal antibody by deoxyspergualin in a murine model.
  Transplantation 1994 Alegre ML, Sattar HA, Herold KC, Smith J, Tepper MA, Bluestone JA
• A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo.
  Transplantation 1994 Alegre ML, Peterson LJ, Xu D, Sattar HA, Jeyarajah DR, Kowalkowski K, Thistlethwaite JR, Zivin RA, Jolliffe L, Bluestone JA
• IL-4 treatment of small splenic B cells induces costimulatory molecules B7-1 and B7-2.
  Journal of immunology (Baltimore, Md. : 1950) 1994 Stack RM, Lenschow DJ, Gray GS, Bluestone JA, Fitch FW
• Prolongation of human pancreatic islet xenografts by pretreatment of islets with anti-human ICAM-1 monoclonal antibody.
  Transplantation proceedings 1994 Zeng Y, Torres MA, Thistlethwaite JR, Montag A, Bluestone JA
• Unique antigen recognition by a herpesvirus-specific TCR-gamma delta cell.
  Journal of immunology (Baltimore, Md. : 1950) 1994 Sciammas R, Johnson RM, Sperling AI, Brady W, Linsley PS, Spear PG, Fitch FW, Bluestone JA
• Cooperation between staphylococcal enterotoxin B and low dose melphalan in the cure of mice bearing a large MOPC-315 tumor and extensive metastases.
  Journal of immunology (Baltimore, Md. : 1950) 1994 Rubin M, Bluestone JA, Newell KA, Prokhorova A, Mokyr MB
• The nature of major histocompatibility complex recognition by gamma delta T cells.
  Cell 1994 Schild H, Mavaddat N, Litzenberger C, Ehrich EW, Davis MM, Bluestone JA, Matis L, Draper RK, Chien YH
• Differential effects of T cell receptor ligation of TCR gamma delta thymocyte development in fetal thymic organ culture.
  Thymus 1994 Tatsumi Y, Deluca D, Cron RQ, Bluestone JA
• TCR gamma delta cells: mysterious cells of the immune system.
  Immunologic research 1994 Sciammas R, Tatsumi Y, Sperling AI, Arunan K, Bluestone JA
• The gamma chain of the high-affinity receptor for IgE is a major functional subunit of the T-cell antigen receptor complex in gamma delta T lymphocytes.
  Proceedings of the National Academy of Sciences of the United States of America 1993 Qian D, Sperling AI, Lancki DW, Tatsumi Y, Barrett TA, Bluestone JA, Fitch FW
• CD28-mediated costimulation is necessary for the activation of T cell receptor-gamma delta+ T lymphocytes.
  Journal of immunology (Baltimore, Md. : 1950) 1993 Sperling AI, Linsley PS, Barrett TA, Bluestone JA
• Expression and functional significance of an additional ligand for CTLA-4.
  Proceedings of the National Academy of Sciences of the United States of America 1993 Lenschow DJ, Su GH, Zuckerman LA, Nabavi N, Jellis CL, Gray GS, Miller J, Bluestone JA
• Role of gamma delta T cells in murine collagen-induced arthritis.
  Journal of immunology (Baltimore, Md. : 1950) 1993 Peterman GM, Spencer C, Sperling AI, Bluestone JA
• T-cell receptor gamma delta diversity and specificity of intestinal intraepithelial lymphocytes: analysis of IEL-derived hybridomas.
  Cellular immunology 1993 Sydora BC, Mixter PF, Houlden B, Hershberg R, Levy R, Comay M, Bluestone J, Kronenberg M
• Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan.
  Journal of immunology (Baltimore, Md. : 1950) 1993 Mokyr MB, Rubin M, Newell KA, Prokhorova A, Bluestone JA
• Peptide-induced changes in class I heavy chains alter allorecognition.
  Journal of immunology (Baltimore, Md. : 1950) 1993 Bluestone JA, Kaliyaperumal A, Jameson S, Miller S, Dick R
• Evidence for programmed cell death of self-reactive gamma delta T cell receptor-positive thymocytes.
  European journal of immunology 1993 Dent AL, Matis LA, Bluestone JA, Hedrick SM
• T cell co-stimulation and in vivo tolerance.
  Current opinion in immunology 1993 Lenschow DJ, Bluestone JA
• Development of T cell receptor-gamma delta cells. Phenotypic and functional correlations of T cell receptor-gamma delta thymocyte maturation.
  Journal of immunology (Baltimore, Md. : 1950) 1993 Tatsumi Y, Pena JC, Matis L, Deluca D, Bluestone JA
• Alloantibodies can discriminate class I major histocompatibility complex molecules associated with various endogenous peptides.
  Proceedings of the National Academy of Sciences of the United States of America 1993 Sherman LA, Chattopadhyay S, Biggs JA, Dick RF, Bluestone JA
• Tolerance of T cell receptor gamma/delta cells in the intestine.
  The Journal of experimental medicine 1993 Barrett TA, Tatsumi Y, Bluestone JA
• Non-classical MHC molecules: the first line of defence?
  Current biology : CB 1993 Sperling AI, Bluestone JA
• Phenotypic and functional analysis of positive selection in the gamma/delta T cell lineage.
  The Journal of experimental medicine 1993 Wells FB, Tatsumi Y, Bluestone JA, Hedrick SM, Allison JP, Matis LA
• Immunosuppressive effects of anti-CD3 MAb and soluble co-stimulatory molecules.
  Transplantation proceedings 1993 Bluestone JA, Bruce D, Peterson L, Thistlethwaite JR, Josephson M, Zeng Y, Linsley PS, Lenschow DJ
• Long-term functional xenograft tolerance after intrathymic islet transplantation (Lewis rat-->B6 mouse).
  Transplantation proceedings 1993 Zeng Y, Bluestone JA, Ildstad ST, Torres MA, Montag AG, Thistlethwaite RJ
• Nonmitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier.
  Journal of immunology (Baltimore, Md. : 1950) 1993 Blazar BR, Taylor PA, Snover DC, Bluestone JA, Vallera DA
• Peptide-induced conformational changes in class I heavy chains alter major histocompatibility complex recognition.
  The Journal of experimental medicine 1992 Bluestone JA, Jameson S, Miller S, Dick R
• Peripheral T cell receptor gamma delta variable gene repertoire maps to the T cell receptor loci and is influenced by positive selection.
  Journal of immunology (Baltimore, Md. : 1950) 1992 Sperling AI, Cron RQ, Decker DC, Stern DA, Bluestone JA
• Differential function of intestinal intraepithelial lymphocyte subsets.
  Journal of immunology (Baltimore, Md. : 1950) 1992 Barrett TA, Gajewski TF, Danielpour D, Chang EB, Beagley KW, Bluestone JA
• Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg.
  Science (New York, N.Y.) 1992 Lenschow DJ, Zeng Y, Thistlethwaite JR, Montag A, Brady W, Gibson MG, Linsley PS, Bluestone JA
• Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody.
  Journal of immunology (Baltimore, Md. : 1950) 1992 Alegre ML, Collins AM, Pulito VL, Brosius RA, Olson WC, Zivin RA, Knowles R, Thistlethwaite JR, Jolliffe LK, Bluestone JA
• Effects of anti-CD3 monoclonal antibody on engraftment of T-cell-depleted bone marrow allografts in mice: host T-cell suppression, growth factors, and space.
  Blood 1992 Hiruma K, Hirsch R, Patchen M, Bluestone JA, Gress RE
• Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression.
  Journal of immunology (Baltimore, Md. : 1950) 1992 Woodle ES, Thistlethwaite JR, Jolliffe LK, Zivin RA, Collins A, Adair JR, Bodmer M, Athwal D, Alegre ML, Bluestone JA
• In vitro and in vivo activation of murine gamma/delta T cells induces the expression of IgA, IgM, and IgG Fc receptors.
  Journal of immunology (Baltimore, Md. : 1950) 1992 Sandor M, Houlden B, Bluestone J, Hedrick SM, Weinstock J, Lynch RG
• The T cell receptor in autoimmune diseases.
  The Journal of rheumatology. Supplement 1992 Bluestone JA, Spencer C, Hirsch R
• Immunoregulatory functions for murine intraepithelial lymphocytes: gamma/delta T cell receptor-positive (TCR+) T cells abrogate oral tolerance, while alpha/beta TCR+ T cells provide B cell help.
  The Journal of experimental medicine 1992 Fujihashi K, Taguchi T, Aicher WK, McGhee JR, Bluestone JA, Eldridge JH, Kiyono H
• Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody.
  Diabetes 1992 Herold KC, Bluestone JA, Montag AG, Parihar A, Wiegner A, Gress RE, Hirsch R
• A murine CD4-, CD8- T cell receptor-gamma delta T lymphocyte clone specific for herpes simplex virus glycoprotein I.
  Journal of immunology (Baltimore, Md. : 1950) 1992 Johnson RM, Lancki DW, Sperling AI, Dick RF, Spear PG, Fitch FW, Bluestone JA
• A protective role of gamma/delta T cells in primary infection with Listeria monocytogenes in mice.
  The Journal of experimental medicine 1992 Hiromatsu K, Yoshikai Y, Matsuzaki G, Ohga S, Muramori K, Matsumoto K, Bluestone JA, Nomoto K
• Activation of T cells in vivo using anti-CD3 and staphylococcal enterotoxins.
  International journal of cancer. Supplement = Journal international du cancer. Supplement 1992 Bluestone JA, Bruce DS, Newell KA
• Mechanism of self-tolerance of gamma/delta T cells in epithelial tissue.
  The Journal of experimental medicine 1992 Barrett TA, Delvy ML, Kennedy DM, Lefrancois L, Matis LA, Dent AL, Hedrick SM, Bluestone JA
• Immunopotentiation of anti-viral and anti-tumor immune responses using anti-T cell receptor antibodies and mitogens.
  Annals of the New York Academy of Sciences 1991 Newell KA, Ellenhorn JD, Hirsch R, Bluestone JA
• Inter-mouse strain differences in the in vivo anti-CD3 induced cytokine release.
  Clinical and experimental immunology 1991 Ferran C, Dy M, Sheehan K, Merite S, Schreiber R, Landais P, Grau G, Bluestone J, Bach JF, Chatenoud L
• Novel function for intestinal intraepithelial lymphocytes. Murine CD3+, gamma/delta TCR+ T cells produce IFN-gamma and IL-5.
  Journal of immunology (Baltimore, Md. : 1950) 1991 Taguchi T, Aicher WK, Fujihashi K, Yamamoto M, McGhee JR, Bluestone JA, Kiyono H
• CD4-CD8- thymocytes from MRL-lpr/lpr mice exhibit abnormal proportions of alpha beta- and gamma delta-TCR+ cells and demonstrate defective responsiveness when activated through the TCR.
  Cellular immunology 1991 Kakkanaiah VN, Nagarkatti M, Bluestone JA, Nagarkatti PS
• Cascade modulation by anti-tumor necrosis factor monoclonal antibody of interferon-gamma, interleukin 3 and interleukin 6 release after triggering of the CD3/T cell receptor activation pathway.
  European journal of immunology 1991 Ferran C, Dy M, Sheehan K, Schreiber R, Grau G, Bluestone J, Bach JF, Chatenoud L
• Requirement for positive selection of gamma delta receptor-bearing T cells.
  Science (New York, N.Y.) 1991 Wells FB, Gahm SJ, Hedrick SM, Bluestone JA, Dent A, Matis LA
• Anti-CD3 monoclonal antibody therapy. An approach toward optimization by in vitro analysis of new anti-CD3 antibodies.
  Transplantation 1991 Woodle ES, Thistlethwaite JR, Jolliffe LK, Fucello AJ, Stuart FP, Bluestone JA
• OKT3 F(ab')2 fragments--retention of the immunosuppressive properties of whole antibody with marked reduction in T cell activation and lymphokine release.
  Transplantation 1991 Woodle ES, Thistlethwaite JR, Ghobrial IA, Jolliffe LK, Stuart FP, Bluestone JA
• Repertoire development and ligand specificity of murine TCR gamma delta cells.
  Immunological reviews 1991 Bluestone JA, Cron RQ, Barrett TA, Houlden B, Sperling AI, Dent A, Hedrick S, Rellahan B, Matis LA
• Specificity of gamma delta receptor bearing T cells.
  Seminars in immunology 1991 Matis LA, Bluestone JA
• Advantages of F(ab')2 fragments of anti-CD3 monoclonal antibody as compared to whole antibody as immunosuppressive agents in mice.
  Transplantation proceedings 1991 Hirsch R, Bluestone JA, Bare CV, Gress RE
• In vivo T-cell activation by staphylococcal enterotoxin B prevents outgrowth of a malignant tumor.
  Proceedings of the National Academy of Sciences of the United States of America 1991 Newell KA, Ellenhorn JD, Bruce DS, Bluestone JA
• Junctional sequences influence the specificity of gamma/delta T cell receptors.
  The Journal of experimental medicine 1991 Rellahan BL, Bluestone JA, Houlden BA, Cotterman MM, Matis LA
• T-cell activation and lymphokine production induced by antihuman CD3 monoclonal antibodies.
  Transplantation proceedings 1991 Woodle ES, Thistlethwaite JR, Jolliffe LK, Ghobrial I, Fuccello AJ, Stuart FP, Bluestone JA
• Signal transduction through class I MHC by a monoclonal antibody that detects multiple murine and human class I molecules.
  Journal of immunology (Baltimore, Md. : 1950) 1991 Houlden BA, Widacki SM, Bluestone JA
• Control of self-reactivity in the intestine.
  Immunologic research 1991 Barrett TA, Hedrick SM, Dent AL, Delvy ML, Kennedy DM, Matis LA, Bluestone JA
• Ligand specificity and repertoire development of murine TCR gamma delta cells.
  Current topics in microbiology and immunology 1991 Bluestone JA, Cron RQ, Rellahan B, Matis LA
• Selection of V delta+ T cell receptors of intestinal intraepithelial lymphocytes is dependent on class II histocompatibility antigen expression.
  Current topics in microbiology and immunology 1991 Lefrancois L, LeCorre R, Mayo J, Bluestone JA, Goodman T
• Freshly isolated Thy-1+ dendritic epidermal cells express T cell receptor gamma delta-CD3.
  Journal of dermatological science 1990 Shimada S, Caughman SW, Bluestone JA, Cron RQ, Owen FL, Smith JA, Katz SI
• T lymphocyte activation following OKT3 treatment.
  Current surgery 1990 Ellenhorn JD, Woodle ES, Thistlethwaite JR, Bluestone JA
• Extrathymic selection of TCR gamma delta + T cells by class II major histocompatibility complex molecules.
  Cell 1990 Lefrancois L, LeCorre R, Mayo J, Bluestone JA, Goodman T
• Activation of human T cells in vivo following treatment of transplant recipients with OKT3.
  Transplantation 1990 Ellenhorn JD, Woodle ES, Ghobreal I, Thistlethwaite JR, Bluestone JA
• Reduction of morbidity and cytokine release in anti-CD3 MoAb-treated mice by corticosteroids.
  Transplantation 1990 Ferran C, Dy M, Merite S, Sheehan K, Schreiber R, Leboulenger F, Landais P, Bluestone J, Bach JF, Chatenoud L
• Treatment with monoclonal anti-CD3 antibody protects against lethal Sendai virus infection by induction of natural killer cells.
  Journal of immunology (Baltimore, Md. : 1950) 1990 Kast WM, Bluestone JA, Heemskerk MH, Spaargaren J, Voordouw AC, Ellenhorn JD, Melief CJ
• Structural basis of Kbm8 alloreactivity. Amino acid substitutions on the beta-pleated floor of the antigen recognition site.
  Journal of immunology (Baltimore, Md. : 1950) 1990 Hunt HD, Pullen JK, Dick RF, Bluestone JA, Pease LR
• T cell receptor delta-gene expression and diversity in the mouse spleen.
  Journal of immunology (Baltimore, Md. : 1950) 1990 Ezquerra A, Cron RQ, McConnell TJ, Valas RB, Bluestone JA, Coligan JE
• Neurotoxicity after treatment with muromonab-CD3.
  The New England journal of medicine 1990 Richards JM, Vogelzang NJ, Bluestone JA
• In vivo T lymphocyte activation induced in mice following the injection of anti-CD3 monoclonal antibody.
  Transplantation proceedings 1990 Ferran C, Bluestone J, Bach JF, Chatenoud L
• Expression of a T cell receptor gamma-chain (V gamma 1.1J gamma 4C gamma 4) transgene in mice influences T cell receptor ontogeny and thymic architecture during development.
  Journal of immunology (Baltimore, Md. : 1950) 1990 Ferrick DA, Chan A, Rahemtulla A, Widacki SM, Xia M, Broughton H, Gajewski DA, Ballhausen W, Allison JP, Bluestone JA
• Anti-CD3 F(ab')2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb.
  Transplantation 1990 Hirsch R, Bluestone JA, DeNenno L, Gress RE
• Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice.
  Journal of immunology (Baltimore, Md. : 1950) 1990 Ellenhorn JD, Schreiber H, Bluestone JA
• Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation.
  European journal of immunology 1990 Ferran C, Sheehan K, Dy M, Schreiber R, Merite S, Landais P, Noel LH, Grau G, Bluestone J, Bach JF
• Self-reactive gamma delta T cells are eliminated in the thymus.
  Nature 1990 Dent AL, Matis LA, Hooshmand F, Widacki SM, Bluestone JA, Hedrick SM
• Cloning of an interleukin-4 inducible gene from cytotoxic T lymphocytes and its identification as a lipase.
  Cell 1990 Grusby MJ, Nabavi N, Wong H, Dick RF, Bluestone JA, Schotz MC, Glimcher LH
• Polymorphisms and diversity of T-cell receptor-gamma proteins expressed in mouse spleen.
  Immunogenetics 1990 Cron RQ, Coligan JE, Bluestone JA
• Identification of distinct T cell receptor (TCR)-gamma delta heterodimers using an anti-TCR-gamma variable region serum.
  Journal of immunology (Baltimore, Md. : 1950) 1989 Cron RQ, Ezquerra A, Coligan JE, Houlden BA, Bluestone JA, Maloy WL
• Structure and specificity of a class II MHC alloreactive gamma delta T cell receptor heterodimer.
  Science (New York, N.Y.) 1989 Matis LA, Fry AM, Cron RQ, Cotterman MM, Dick RF, Bluestone JA
• Anti-CD3 antibody for autoimmune disease, a cautionary note.
  Lancet (London, England) 1989 Hirsch R, Gress RE, Bluestone JA
• Phenotypic and functional analysis of murine CD3+,CD4-,CD8- TCR-gamma delta-expressing peripheral T cells.
  Journal of immunology (Baltimore, Md. : 1950) 1989 Cron RQ, Gajewski TF, Sharrow SO, Fitch FW, Matis LA, Bluestone JA
• Suppression of the humoral response to anti-CD3 monoclonal antibody.
  Transplantation 1989 Hirsch R, Chatenoud L, Gress RE, Sachs DH, Bach JF, Bluestone JA
• TCR gamma delta cells--minor redundant T cell subset or specialized immune system component?
  Journal of immunology (Baltimore, Md. : 1950) 1989 Bluestone JA, Matis LA
• Dose-dependent activation of murine T cells following in vivo administration of anti-murine CD3.
  Transplantation proceedings 1989 Ellenhorn JD, Hirsch R, Hartley JP, Bluestone JA
• Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells.
  Journal of immunology (Baltimore, Md. : 1950) 1989 Hirsch R, Gress RE, Pluznik DH, Eckhaus M, Bluestone JA
• Suppression of the humoral response to anti-CD3 mAB by pretreatment with anti-CD4 mAB.
  Transplantation proceedings 1989 Hirsch R, Chatenoud L, Gress RE, Bach JF, Sachs DH, Bluestone JA
• Substitution at residue 227 of H-2 class I molecules abrogates recognition by CD8-dependent, but not CD8-independent, cytotoxic T lymphocytes.
  Nature 1989 Potter TA, Rajan TV, Dick RF, Bluestone JA
• A TCR gamma delta cell recognizing a novel TL-encoded gene product.
  Cold Spring Harbor symposia on quantitative biology 1989 Houlden BA, Matis LA, Cron RQ, Widacki SM, Brown GD, Pampeno C, Meruelo D, Bluestone JA
• T cell clones and monoclonal antibodies: immunologic probes of major histocompatibility complex class I molecules.
  Chemical immunology 1989 Bluestone JA, Potter T
• T helper 2 (Th2) but not Th1 clones co-stimulate resting T cells in the presence of anti-CD3 monoclonal antibody.
  International immunology 1989 Evavold BD, Yokoyama A, Hirsch R, Bluestone JA, Quintans J
• Systematic development of distinct T cell receptor-gamma delta T cell subsets during fetal ontogeny.
  Journal of immunology (Baltimore, Md. : 1950) 1988 Houlden BA, Cron RQ, Coligan JE, Bluestone JA
• Structure and specificity of T cell receptor gamma/delta on major histocompatibility complex antigen-specific CD3+, CD4-, CD8- T lymphocytes.
  The Journal of experimental medicine 1988 Bluestone JA, Cron RQ, Cotterman M, Houlden BA, Matis LA
• In vivo administration of anti-CD3 prevents malignant progressor tumor growth.
  Science (New York, N.Y.) 1988 Ellenhorn JD, Hirsch R, Schreiber H, Bluestone JA
• Peripheral murine CD3+, CD4-, CD8- T lymphocytes express novel T cell receptor gamma delta structures.
  Journal of immunology (Baltimore, Md. : 1950) 1988 Cron RQ, Koning F, Maloy WL, Pardoll D, Coligan JE, Bluestone JA
• CD3-associated heterodimeric polypeptides on suppressor hybridomas define biologically active inhibitory cells.
  Proceedings of the National Academy of Sciences of the United States of America 1988 Weiner DB, Liu J, Hanna N, Bluestone JA, Coligan JE, Williams WV, Greene MI
• Cytotoxic T lymphocyte recognition of novel allodeterminants expressed on in vitro selected H-2Kb mutants.
  Journal of immunology (Baltimore, Md. : 1950) 1988 Lewis J, Foo M, Geier SS, Kumar PA, Nathenson SG, Bluestone JA
• Evidence that multiple residues on both the alpha-helices of the class I MHC molecule are simultaneously recognized by the T cell receptor.
  Cell 1988 Ajitkumar P, Geier SS, Kesari KV, Borriello F, Nakagawa M, Bluestone JA, Saper MA, Wiley DC, Nathenson SG
• Selective expression of the Ly-6C.2 epitope on Lyt-2+ T cells that can develop in the absence of thymic influence.
  Journal of immunology (Baltimore, Md. : 1950) 1988 Leo O, Foo M, Forman J, Shivakumar S, Rabinowitz R, Bluestone JA
• The alpha-3 domain of class I MHC proteins influences cytotoxic T lymphocyte recognition of antigenic determinants located within the alpha-1 and alpha-2 domains.
  Journal of immunology (Baltimore, Md. : 1950) 1988 Maziarz RT, Burakoff SJ, Bluestone JA
• Thymus-dependent and thymus-independent developmental pathways for peripheral T cell receptor-gamma delta-bearing lymphocytes.
  Journal of immunology (Baltimore, Md. : 1950) 1988 Pardoll DM, Fowlkes BJ, Lew AM, Maloy WL, Weston MA, Bluestone JA, Schwartz RH, Coligan JE, Kruisbeek AM
• Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses.
  Journal of immunology (Baltimore, Md. : 1950) 1988 Hirsch R, Eckhaus M, Auchincloss H, Sachs DH, Bluestone JA
• Proliferation and production of IL-2 and B cell stimulatory factor 1/IL-4 in early fetal thymocytes by activation through Thy-1 and CD3.
  Journal of immunology (Baltimore, Md. : 1950) 1988 Tentori L, Pardoll DM, Zuñiga JC, Hu-Li J, Paul WE, Bluestone JA, Kruisbeek AM
• Class II antigen-specific murine cytolytic T lymphocytes (CTL). II. Genuine class II specificity of Lyt-2+ CTL clones.
  Journal of immunology (Baltimore, Md. : 1950) 1988 Shinohara N, Hozumi N, Watanabe M, Bluestone JA, Johnson-Leva R, Sachs DH
• In vivo administration of anti-CD3 monoclonal antibody can activate immune responses thus preventing malignant tumor growth.
  Princess Takamatsu symposia 1988 Hirsch R, Ellenhorn JD, Bluestone JA
• Inhibition of transformed T cell growth in vitro by monoclonal antibodies directed against distinct activating molecules.
  Journal of immunology (Baltimore, Md. : 1950) 1988 Mercep M, Bluestone JA, Noguchi PD, Ashwell JD
• Role of Ti/CD3, Thy-1, and Ly-6 in cytolytic T-cell activation analyzed with Ti loss variants.
  Annals of the New York Academy of Sciences 1988 Langlet C, Guimezanes A, Kaldy P, Boyer C, Buferne M, Poenie M, Tsien R, Leo O, Bluestone J, Leserman L
• Role of accessory molecules in signal transduction of cytolytic T lymphocyte by anti-T cell receptor and anti-Ly-6.2C monoclonal antibodies.
  Journal of immunology (Baltimore, Md. : 1950) 1987 Leo O, Foo M, Henkart PA, Perez P, Shinohara N, Segal DM, Bluestone JA
• Structure and expression of class I MHC genes in the miniature swine.
  Veterinary immunology and immunopathology 1987 Singer DS, Ehrlich R, Satz L, Frels W, Bluestone J, Hodes R, Rudikoff S
• Major histocompatibility complex-linked specificity of gamma delta receptor-bearing T lymphocytes.
  Nature 1987 Matis LA, Cron R, Bluestone JA
• T cell antigen receptor phosphorylation induced by an anti-receptor antibody.
  Journal of immunology (Baltimore, Md. : 1950) 1987 Samelson LE, O'Shea JJ, Luong H, Ross P, Urdahl KB, Klausner RD, Bluestone J
• A single amino acid substitution in the alpha 3 domain of an H-2 class I molecule abrogates reactivity with CTL.
  The Journal of experimental medicine 1987 Potter TA, Bluestone JA, Rajan TV
• T cell receptor tyrosine phosphorylation. Variable coupling for different activating ligands.
  The Journal of biological chemistry 1987 Klausner RD, O'Shea JJ, Luong H, Ross P, Bluestone JA, Samelson LE
• Activation of murine T lymphocytes with monoclonal antibodies: detection on Lyt-2+ cells of an antigen not associated with the T cell receptor complex but involved in T cell activation.
  Journal of immunology (Baltimore, Md. : 1950) 1987 Leo O, Foo M, Segal DM, Shevach E, Bluestone JA
• Cytotoxic T lymphocyte recognition of a xenogeneic major histocompatibility complex antigen expressed in transgenic mice.
  European journal of immunology 1987 Bluestone JA, Pescovitz MD, Frels WI, Singer DS, Hodes RJ
• Thy-1+ dendritic epidermal cells express T3 antigen and the T-cell receptor gamma chain.
  Proceedings of the National Academy of Sciences of the United States of America 1987 Stingl G, Koning F, Yamada H, Yokoyama WM, Tschachler E, Bluestone JA, Steiner G, Samelson LE, Lew AM, Coligan JE
• Production of a T cell hybridoma that expresses the T cell receptor gamma/delta heterodimer.
  The Journal of experimental medicine 1987 Yokoyama WM, Koning F, Stingl G, Bluestone JA, Coligan JE, Shevach EM
• Characterization of murine thymocytes with CD3-associated T-cell receptor structures.
  Nature 1987 Bluestone JA, Pardoll D, Sharrow SO, Fowlkes BJ
• Differential expression of two distinct T-cell receptors during thymocyte development.
  Nature 1987 Pardoll DM, Fowlkes BJ, Bluestone JA, Kruisbeek A, Maloy WL, Coligan JE, Schwartz RH
• Identification of a monoclonal antibody specific for a murine T3 polypeptide.
  Proceedings of the National Academy of Sciences of the United States of America 1987 Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA
• Antigen receptor-triggered secretion of a trypsin-type esterase from cytotoxic T lymphocytes.
  Journal of immunology (Baltimore, Md. : 1950) 1987 Takayama H, Trenn G, Humphrey W, Bluestone JA, Henkart PA, Sitkovsky MV
• Analysis of T-cell receptor gamma chain expression in the thymus.
  Advances in experimental medicine and biology 1987 Pardoll DM, Lew AM, Maloy WL, Fowlkes BJ, Kruisbeek A, Bluestone JA, Schwartz RH, Coligan JE
• Analysis of structure/function relationships among major histocompatibility complex class I antigens.
  Immunologic research 1987 Bluestone JA
• Analysis of hybrid H-2D and L antigens with reciprocally mismatched aminoterminal domains: functional T cell recognition requires preservation of fine structural determinants.
  Journal of immunology (Baltimore, Md. : 1950) 1986 McCluskey J, Boyd L, Foo M, Forman J, Margulies DH, Bluestone JA
• Identification of monoclonal antibodies specific for the T cell receptor complex by Fc receptor-mediated CTL lysis.
  Journal of immunology (Baltimore, Md. : 1950) 1986 Leo O, Sachs DH, Samelson LE, Foo M, Quinones R, Gress R, Bluestone JA
• Characterization of T cell receptor gamma chain expression in a subset of murine thymocytes.
  Science (New York, N.Y.) 1986 Lew AM, Pardoll DM, Maloy WL, Fowlkes BJ, Kruisbeek A, Cheng SF, Germain RN, Bluestone JA, Schwartz RH, Coligan JE
• Expression and function of asialo GM1 in alloreactive cytotoxic T lymphocytes.
  Journal of immunology (Baltimore, Md. : 1950) 1986 Ting CC, Bluestone JA, Hargrove ME, Loh NN
• Somatic cell variants express altered H-2Kb allodeterminants recognized by cytolytic T cell clones.
  Journal of immunology (Baltimore, Md. : 1950) 1986 Bluestone JA, Langlet C, Geier SS, Nathenson SG, Foo M, Schmitt-Verhulst AM
• Cross-reactive recognition by antigen-specific, major histocompatibility complex-restricted T cells of a mitogen derived from Mycoplasma arthritidis is clonally expressed and I-E restricted.
  European journal of immunology 1986 Lynch DH, Cole BC, Bluestone JA, Hodes RJ
• Alloresistance to engraftment of allogeneic donor bone marrow is mediated by an Lyt-2+ T cell in mixed allogeneic reconstitution (C57BL/10Sn + B10.D2/nSn----C57BL/10Sn).
  The Journal of experimental medicine 1986 Ildstad ST, Bluestone JA, Sachs DH
• Cloned cytotoxic T lymphocytes that recognize an I-A region product in the context of a class I antigen.
  The Journal of experimental medicine 1986 Shinohara N, Bluestone JA, Sachs DH
• Idiotypic manipulation of the immune response to transplantation antigens.
  Immunological reviews 1986 Bluestone JA, Leo O, Epstein SL, Sachs DH
• Serologic and T cell recognition of truncated transplantation antigens encoded by in vitro deleted class I major histocompatibility genes.
  Journal of immunology (Baltimore, Md. : 1950) 1986 McCluskey J, Bluestone JA, Coligan JE, Maloy WL, Margulies DH
• Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).
  Journal of immunology (Baltimore, Md. : 1950) 1986 Ildstad ST, Wren SM, Bluestone JA, Barbieri SA, Stephany D, Sachs DH
• Evidence for a regulatory idiotypic network in the in vivo response to H-2 antigens.
  The Journal of experimental medicine 1985 Rabinowitz R, Bluestone JA, Sachs DH
• Allospecific cytolytic T lymphocytes recognize conformational determinants on hybrid mouse transplantation antigens.
  The Journal of experimental medicine 1985 Bluestone JA, Foo M, Allen H, Segal D, Flavell RA
• Characterization of mixed allogeneic chimeras. Immunocompetence, in vitro reactivity, and genetic specificity of tolerance.
  The Journal of experimental medicine 1985 Ildstad ST, Wren SM, Bluestone JA, Barbieri SA, Sachs DH
• Lysis of anti-T3-bearing murine hybridoma cells by human allospecific cytotoxic T cell clones and inhibition of that lysis by anti-T3 and anti-LFA-1 antibodies.
  Journal of immunology (Baltimore, Md. : 1950) 1985 Hoffman RW, Bluestone JA, Leo O, Shaw S
• Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody.
  Nature 1985 Perez P, Hoffman RW, Shaw S, Bluestone JA, Segal DM
• Generation of primary murine CTL specific for allogeneic and xenogeneic MHC determinants upon stimulation with murine L cells transfected with class I genes.
  Journal of immunology (Baltimore, Md. : 1950) 1985 Golding H, Bluestone J, Satz ML, Singer D, Singer A
• Expression of a microinjected porcine class I major histocompatibility complex gene in transgenic mice.
  Science (New York, N.Y.) 1985 Frels WI, Bluestone JA, Hodes RJ, Capecchi MR, Singer DS
• Molecular localization of allogeneic and self determinants recognized by bulk and clonal populations of cytotoxic T cells.
  Journal of immunology (Baltimore, Md. : 1950) 1985 Levy RB, Ozato K, Richardson JC, Bluestone JA
• Quantitative measurements of the specificity and kinetics of conjugate formation between cloned cytotoxic T lymphocytes and splenic target cells by dual parameter flow cytometry.
  Journal of immunology (Baltimore, Md. : 1950) 1985 Perez P, Bluestone JA, Stephany DA, Segal DM
• The role of cytoplasmic granules in cytotoxicity by large granular lymphocytes and cytotoxic T lymphocytes.
  Advances in experimental medicine and biology 1985 Henkart P, Henkart M, Millard P, Frederikse P, Bluestone J, Blumenthal R, Yue C, Reynolds C
• The regulation of the immune system.
  Immunology today 1984 Hodes RJ, Germain RN, Bluestone JA
• CTL recognize different determinants from those defined serologically on Ld somatic cell mutants.
  Journal of immunology (Baltimore, Md. : 1950) 1984 Bluestone JA, Potter TA, Chatterjee-Hasrouni S, Rajan TV
• Serological analysis of H-2 mutations using monoclonal antibodies.
  Journal of immunogenetics 1984 Bluestone JA, McKenzie IF, Melvold RW, Ozato K, Sandrin MS, Sharrow SO, Sachs DH
• Cell-surface molecules involved in T-cell functions.
  Immunology today 1983 Bluestone JA, Hodes RJ
• Anti-idiotypes against anti-H-2 antibodies VI. Detection of shared idiotypes among monoclonal anti-H-2 antibodies.
  European journal of immunology 1983 Bluestone JA, Auchincloss H, Sachs DH, Fibi M, Hämmerling GJ
• Antiidiotypes against anti-H-2 monoclonal antibodies. V. In vivo antiidiotype treatment induces idiotype-specific helper T cells.
  The Journal of experimental medicine 1983 Auchincloss H, Bluestone JA, Sachs DH
• Idiotypes of anti-major histocompatibility complex antibodies.
  Annals of the New York Academy of Sciences 1983 Sachs DH, Bluestone JA, Epstein SL, Rabinowitz R
• Suppression of the immune response in tumor-bearing mice. III. Induction of functionally suppressive antigen-driven macrophages.
  Cancer investigation 1983 Bluestone JA, Lopez C
• The presence of a common idiotype in anti-H-2 immune sera as detected by anti-idiotype to a monoclonal anti-H-2 antibody.
  European journal of immunology 1983 Ozato K, Epstein SL, Bluestone JA, Sharrow SO, Hansen T, Sachs DH
• Anti-idiotypes against anti-H-2 monoclonal antibodies: structural analysis of the molecules induced by in vivo anti-idiotype treatment.
  Proceedings of the National Academy of Sciences of the United States of America 1982 Bluestone JA, Krutzsch HC, Auchincloss H, Cazenave PA, Kindt TJ, Sachs DH
• Anti-idiotypes to monoclonal anti-H-2 antibodies. III. Syngeneic anti-idiotypes on antibodies induced by in vivo administration of xenogeneic anti-idiotypes.
  Journal of immunology (Baltimore, Md. : 1950) 1982 Bluestone JA, Auchincloss H, Cazenave PA, Ozato K, Sachs DH
• Idiotypes of anti-Ia antibodies. II. Effects of in vivo treatment with xenogeneic anti-idiotype.
  Journal of immunology (Baltimore, Md. : 1950) 1982 Epstein SL, Masakowski VR, Sharrow SO, Bluestone JA, Ozato K, Sachs DH
• Induction of gp70-specific suppressor T-cells in mice inoculated with virus-producing tumor cells.
  Journal of the National Cancer Institute 1982 Bluestone JA, Lopez C
• Anti-idiotypes to monoclonal anti-H-2 antibodies--I. Contribution of isolated heavy and light chains to idiotype expression.
  Molecular immunology 1982 Bluestone JA, Metzger JJ, Knode MC, Ozato K, Sachs DH
• Anti-idiotypes to monoclonal anti-H-2 antibodies. II. Expression of anti-H-2Kk idiotypes on antibodies induced by anti-idiotype or H-2Kk antigen.
  The Journal of experimental medicine 1981 Bluestone JA, Epstein SL, Ozato K, Sharrow SO, Sachs DH
• Idiotypes of anti-Ia antibodies. I. Expression of the 14-4-4S idiotype in humoral immune responses.
  The Journal of experimental medicine 1981 Epstein SL, Ozato K, Bluestone JA, Sachs DH
• Mixed lymphocyte reactivity in spleen cells from F-9 tumor-bearing ice. I. Suppressor cell induction and characterization.
  Cellular immunology 1981 Bluestone JA, Lopez C, Hurtenbach U
• Mixed lymphocyte reactivity in spleen cells from F-9 tumor-bearing mice. II. Functional cross-reactivity between F-9 cells and testicular cells.
  Cellular immunology 1981 Hurtenbach U, Bennett D, Bluestone JA
• Induction of anti-H-2 antibodies without alloantigen exposure by in vivo administration of anti-idiotype.
  Nature 1981 Bluestone JA, Sharrow SO, Epstein SL, Ozato K, Sachs DH
• Antiidiotypes to monoclonal anti-H-2 and anti-Ia hybridoma antibodies.
  Transplantation proceedings 1981 Sachs DH, Bluestone JA, Epstein SL, Ozato K
• Suppression of the immune response in tumor-bearing mice. I. Response to virus-producing tumor cells and non-virus-producing tumor cells.
  Journal of the National Cancer Institute 1979 Bluestone JA, Lopez C
• Suppression of the immune response in tumor-bearing mice. II. Characterization of adherent suppressor cells.
  Journal of the National Cancer Institute 1979 Bluestone JA, Lopez C